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Abstract  
 
Title: Investigating the relationship between miRNA expression and epithelial mesenchymal 
transition (EMT) in colorectal cancer. 
Introduction: Epithelial-mesenchymal transition (EMT) is characterized by the loss of an 
epithelial phenotype and gain of a mesenchymal phenotype, i.e., migratory and metastatic 
properties. The EMT process is therefore characterized by a low expression of E-cadherin and 
high expression of mesenchymal markers (e.g., N-cadherin, snail and vimentin). It is stated that 
cells which have undergone EMT also gain stem cell features. Therefore, both EMT and stem 
cell phenotypes have been implicated in carcinogenesis and metastasis of tumour cells. 
Furthermore, EMT is regulated by small non-coding molecules (miRNAs) that either function 
as tumour suppressors or oncogenes (oncomirs). Tumour suppressor miRNAs reverse EMT 
while oncomirs activate it. Therefore, investigating the relationship between miRNAs and 
EMT is important in addressing metastasis of colorectal cancers (CRC).  
Aims and Objectives: The aim of the study was to determine the association between miRNA 
(miRNA-21 and miRNA-34a) expression levels and EMT in CRC. In addition, this 
investigation aimed to correlate miRNA and EMT data with clinicopathologic features of the 
study cohort.   
Methodology: A total of 100 CRC (including 8 known HNPCC cases) Formalin Fixed Paraffin 
Embedded (FFPE) tissue blocks and their corresponding H&E slides were collected from the 
archives of the Division of Anatomical Pathology at the University of Cape Town. 
Subsequently, the FFPE tissue blocks were sectioned at 3µm and IHC analysis of 4 EMT 
markers (E-cadherin, N-cadherin, snail-1 and vimentin) and 1 stem cell marker (CD44V6) was 
performed. The stains were then evaluated and scored by a pathologist. The IHC data were then 
correlated with clinicopathologic features. Furthermore, 59 cases (FFPE tissues and 
corresponding H&E slides) which included the 8 HNPCCs were randomly selected for miRNA 
analysis. The H&Es were examined by a pathologist to demarcate normal and tumour regions. 
RNA was then extracted from 59 tumours and 12 normal tissues using a High Pure FFPET 
Isolation Kit (Roche). Subsequently, cDNA was synthesized and qRT-PCR was performed to 
determine the expression levels of miRNA-21 and miRNA-34a. MiRNA-21 and miRNA-34a 
expression levels were ascertained using the relative quantification method. Moreover, the 
clinical significance of the two miRNAs was evaluated in relation to MSI status. Therefore, 
IHC analysis of MLH1, MSH2 and MSH6 mismatch repair proteins was performed on the 
Ventana platform. Statistical analysis was performed using Fisher’s and Pearson’s Chi Square 
 ix 
 
tests in Stata 12 to correlate EMT and clinicopathologic data. Additionally, the Mann-Whitney 
non-parametric test in GraphPad prism 6 was used to determine miRNA-21 and miRNA-34a 
expression in relation to EMT and MSI data. 
Results: Our results showed low expression of E-cadherin in 77% of cases. In addition, there 
was decreased expression of N-cadherin and vimentin in 98% whilst snail-1 expression was 
decreased in 65% of the cases. Low expression of CD44v6 was also seen in 78% of the cases. 
There was no correlation between EMT/stem cell markers and clinicopathologic data. 
Furthermore, increased miRNA-21 expression was significantly associated with grade, lymph 
node metastasis and age of patients. There was a significant correlation between high miRNA-
21 expression and down-regulated snail-1 and N-cadherin expression. MiRNA-34a expression 
was not associated with any of the clinicopathologic features. In addition, high miRNA-34a 
expression was linked with low expression of snail-1 and CD44v6. Increased miRNA-21 
expression was related with MSS tumours, whereas there was no relationship between miRNA-
34a and MSI status. 
Conclusion: Our investigation shows that there is an inverse association between miRNA 
(miRNA-21 and miRNA-34a) expression and two EMT (N-cadherin and snail-1) markers in 
our colorectal cancer cohort. Our data also show that both miRNA-21 and miRNA-34a cannot 
be used as biomarkers to determine progression of the cancer. Contrary to previous studies, our 
findings indicate that miRNA-21 does not activate EMT in this CRC cohort. However, similar 
to other studies our results confirm that miRNA-34a may be repressing snail-1 expression, 
thereby inhibiting EMT in the cancer.  
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Chapter One 
 
1. Background 
 
1.1. Colorectal cancer incidence 
 
Colorectal cancer (CRC) is rated as the fourth most frequent malignancy in the world 
(Globocan, 2012). It is the second most frequent cancer in women and the third in men. 
Incidence and death rates are less frequent in developed (e.g., Central and Eastern Europe, 
North America and Eastern Asia) than developing countries (e.g., Central America). CRC is 
also common in all the different parts of Africa: Southern Africa, Northern Africa, Western 
Africa, Middle Africa and Eastern Africa. In South Africa, the estimated incidence rates are 
about 6.1%. Moreover, there are high death rates in the less developed countries, reflecting a 
poor survival of the disease (Globocan, 2012).  
 
1.2. Colorectal cancer subtypes 
 
Colorectal cancer (CRC) develops as a result of the abnormal growth of cells lining the mucosa 
of the colon and rectum. It is classified into sporadic and hereditary (e.g., non-polyposis 
colorectal cancer) types (Martinez-Urena et al., 2013). Sporadic CRC is the most frequent type 
which is commonly seen in older people, especially males. Furthermore, it is seen in the distal 
part of the colon and is often poorly differentiated (Nakanishi et al., 2013). The Hereditary non-
polyposis colorectal cancer (HNPCC) is an autosomal dominant disorder that accounts for 
about 3% to 5% of the disease (Diergaarde et al., 2007). HNPCC is characterized by high 
penetrance, early-onset and an increased risk of certain extra-colonic cancers, including cancers 
of the endometrium, stomach, small bowel, ovary, hepatobiliary tract, renal pelvis, and ureter 
(Lynch et al., 1996). This type is commonly seen in the proximal colon. The pathogenesis of 
sporadic and hereditary types of CRC is associated with environmental and genetic risk factors.  
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1.3. Risk factors 
 
Several risk factors are attributed to the development of colorectal cancer and these involve 
environmental, genetic and epigenetic factors (changes in biological pathways).  
 
1.3.1. Environmental risk factors 
 
Various environmental factors are implicated in carcinogenesis and these include dietary 
factors, poor nutrition and tobacco smoking.  
 
1.3.1.1. Dietary factors and poor nutrition 
 
An imbalanced diet has also been identified as a common factor that is linked with the 
development of colorectal cancer. A diet lacking in fresh fruit and vegetables as well as dairy 
products is usually deficient in vitamins A, C and E (Mahfouz et al., 2014). The lower intake 
of these nutrients may cause the colorectal mucosa to be more predisposed to carcinogens. 
Furthermore, the absence of trace elements such as zinc, selenium, molybdenum, silicon, 
nickel, iron, iodine, phosphorus, potassium and magnesium from the diet have also been 
reported as risk factors (Song et al., 2015). Moreover, a high intake of nitrosamines and 
nitrosamine precursors (nitrates, nitrites, secondary and tertiary amines) are also major risk 
factors (Santarelli et al., 2008).   
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1.3.1.2. Tobacco Smoking  
 
Both smoking and excessive alcohol consumption are also considered as important risk factors 
for the disease (Klarich et al., 2015). It has been hypothesised that smoking together with 
alcohol (which acts as a solvent) is detrimental to the development of the disease (Gao et al., 
2013). Furthermore, tobacco is considered as carcinogenic when used in any form: e.g., 
cigarettes, pipe tobacco, cigar, snuff and chewing tobacco. However, pipe and hand-rolled 
cigarette smoking are more carcinogenic than commercial cigarette smoking (Lindsay et al., 
2009).  
 
1.3.2. Genetic factors 
 
Changes or mutations in oncogenes, tumour suppressor, DNA repair and cell cycle genes may 
predispose individuals to developing cancer.  
 
1.3.2.1. Oncogenes 
 
Previous investigations indicated that cells could be transformed in culture by DNA viruses 
and retroviruses. Genes having a similar sequence to those of the viruses were seen in the DNA 
of normal cells (Freeman, 2000). Those genes regulate cell growth and differentiation; however 
when they are abnormally activated, they can lead to the development of cancer. The normal 
cellular genes are called proto-oncogenes and their activated forms are named oncogenes 
(Cooper, 2000). Oncogenes contribute to the development of cancer by promoting cell 
proliferation or reducing apoptosis. In cancers, proto-oncogenes are activated by genetic 
mutations, namely, point mutations, gene amplifications and chromosomal abnormalities (Pino 
et al., 2010). A single mutation in one of the two gene copies is sufficient to promote abnormal 
growth, therefore, oncogenes are said to be dominant (Freeman, 2000). Several oncogenes have 
been reported to contribute to the initiation of cancer and these include growth factors (B-raf, 
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K-ras, raf, mos, src), transcriptional factors (c-myc, jun, fos), and cell-cycle genes (cyclin D1, 
CDK4), (Freeman, 2000). 
 
1.3.2.2. Tumour Suppressor Genes 
 
Unlike oncogenes, tumour suppressor genes are negative modulators of cell proliferation. 
Tumour suppressor genes function to hinder cell proliferation by inducing apoptosis. However, 
when these genes are mutated, their function is lost, consequently leading to the formation of 
cancer (Yuspa et al., 1994). Knudson (1971) showed that retinoblastoma (Rb), which is a 
childhood tumour, is a result of an inactivation in both copies of the Rb gene (Figure 1.1.). This 
is referred to as the “two hit” hypothesis (Knudson, 1971).  
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Figure 1.  1: The “two hit” hypothesis model showing that in hereditary retinoblastoma, the 
first hit is an inherited mutation while the second hit is a somatic mutation of the second 
allele. In the case of non-hereditary tumours, two somatic mutations affect both alleles of the 
Rb gene (Levine, 1995). 
 
Furthermore, tumour suppressor genes are classified into three subgroups of function i.e., 
gatekeepers, care takers and landscapers (Deininger, 1999; Srivastava et al., 2010). 
Gatekeepers are genes that impede cell growth or stimulate differentiation and apoptosis, e.g., 
APC, Rb, p53 and NF-1 (Ligius, 1993; Gnarra et al., 1994). Germline mutation of a gatekeeper 
gene leads to a cancer risk of at least 100 times greater than in the general population. Caretaker 
genes are involved in DNA repair and maintenance of genomic integrity (Eng et al., 2003). 
Lastly, landscapers are the genes (e.g., TSP-1, NF-1, RB, PTEN and DPC4) which stimulate 
cancer development through tissue dysplasia. These genes modulate tissue morphogenesis, 
intercellular signaling and differentiation (Nigro et al., 1989; Wales et al., 1995; Macleod, 
2000).  
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1.3.2.3. DNA repair genes 
 
DNA repair is a mechanism by which a cell identifies and corrects errors e.g., repeat sequences, 
mismatches and strand breaks which may occur during DNA replication (Wang, 2015). Several 
DNA repair pathways are involved in repairing damaged DNA. These include mismatch repair 
(MMR), base-excision repair (BER), nucleotide-excision repair (NER), translesion synthesis 
(TLS), homologous recombination (HR), non-homologous end joining (NHEJ), Fanconi 
anemia (FA) and O6-methylguanine DNA methyltransferase (MGMT) pathways (Dietlein et 
al., 2014). The most common pathways associated with DNA repair in cancer are the BER, 
NER and MMR. The damage is removed and the DNA sequence is repaired by a DNA 
polymerase in all three pathways. The BER involves enzymes called DNA glycosylases which 
identify a specific type of altered base in DNA and therefore remove it (Alberts et al., 2002).  
Furthermore, the NER system repairs damages in the structure of the DNA double helix.  
 
MMR recognizes incorrect insertions, deletions and mis-incorporations of bases (Potenski and 
Klein, 2014). The incorrect number of bases is then detected by the MutSa (MSH2/MSH6), 
MutSb (MSH2/MSH3) and MutLa (MLH1 and PMS2) complexes of the MMR system. The 
MutSa complex identifies small mismatches whilst MutSb detects large mismatches. 
Additionally, the MutLa complex coordinates base mismatch repair (Perevoztchikova et al., 
2013). Mutations in the DNA repair genes can lead to a failure in their repair function, which 
in turn allows subsequent mutations to accumulate. When these genes fail to repair DNA, 
irreversible DNA damage i.e., double-strand breaks and DNA cross linkages may occur. These 
errors can therefore lead to the initiation of cancer (Torgovnick and Schumacher, 2015). 
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1.3.2.4. Cell cycle genes 
 
The cell cycle is a mechanism by which cells divide. It is divided into gap phase 0 (G0), gap 
phase 1 (G1), DNA synthesis (S), gap phase 2 (G2), and mitosis (M). This pathway is composed 
of proteins i.e. cyclins (G1/S cyclins, S cyclins, M cyclins, G1 cyclins) and cyclin-dependent 
kinases (CDK). These proteins form complexes and therefore modulate the progression from 
one stage of the cell cycle to another (Vermeulen et al., 2003). Checkpoints are identified within 
the cell cycle stages to ensure that events such as DNA synthesis proceed accordingly. If there 
is any DNA damage, the checkpoints arrest the cell cycle until the problem is repaired (Collins 
et al., 1997).  
 
Molecules which regulate the G1/S phase such as proto-oncogenes and tumour suppressor 
genes may undergo alterations and hence contribute towards cancer formation. Additionally, 
checkpoints such as those responsible to check DNA damage and modulate DNA replication 
may also be genetically compromised (Bartek et al., 1999). A number of cell cycle genes have 
been implicated in carcinogenesis and these include p53, cyclin D1, p21, p27, CDK4 and p57 
(McKay et al., 2000).  
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Literature Review 
 
 
1.4. Molecular pathways underlying colorectal carcinogenesis 
 
1.4.1. Fearon and Vogelstein model: adenoma-carcinoma sequence 
 
 
In 1990, Fearon and Vogelstein introduced a model that explained the multistep process to the 
development of CRC. This model suggests that colorectal cancer may develop as a result of 
mutational activation of oncogenes and inactivation of tumour-suppressor genes. Secondly, 
mutations in at least four or five genes are necessary for malignant alteration. Lastly, although 
the genetic mutations commonly arise in a preferred order, the mutations rather than their 
chronologic order, is responsible for determining biologic features of the tumour (Fearon and 
Vogelstein, 1990). Furthermore, CRC develops as a result of the conversion of the normal 
epithelial mucosa from adenomas (benign tumours) to carcinomas (Figure 1.2), (Arends, 2013). 
This conversion is accompanied by genetic mutations of APC, KRAS and TP53 genes 
(Yadamsuren et al 2012; Zauber et al 2013; Hershkovitz et al., 2014).  
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Figure 1.  2: The adenoma-carcinoma sequence involves a transition from normal epithelium 
to adenoma and carcinoma due to acquired molecular events e.g., mutations in three key 
genes (APC, KRAS and P53), (Smith et al., 2002). 
 
1.4.2. Microsatellite instability 
 
 
Microsatellites are short fragments of DNA dispersed throughout the genome that have 
repetitive sequences. Microsatellite instability (MSI) occurs as a result of alterations (decrease 
or increase) in microsatellites. MSI is therefore a form of genetic hyper-mutability that occurs 
in the genes (MLH1, MSH2, MSH3, MSH6, PMS1 and PMS2) that encode DNA mismatch 
repair (MMR) proteins (Arends, 2013). These genetic mutations consequently result in 
defective MMR proteins, causing the inability to correct errors during DNA replication. In 
individuals with CRC, MSI is indicated by the loss of MLH1, MSH2, MSH6 and PMS2 
proteins. In HNPCC patients, the predominantly affected proteins are MLHI and MSH2 due to 
germline mutations of MLH1 and MSH2 genes (Bergine et al., 2009; Sinicrope et al., 2015). 
Other MMR proteins are less affected. These are MSH6 and PMS2 caused by MSH6 and PMS2 
germline mutations (Moreira et al., 2014; Karahan et al., 2015). MSI is seen in 15% of sporadic 
CRCs, as a result of BRAF V600E mutation and the silencing of MLH1 gene through promoter 
hyper-methylation (Veganzones et al., 2015). Since MSI is caused by different genetic changes: 
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(e.g., MLH1 hyper-methylation in sporadic cancers and MLH1/MSH2 germline mutations in 
HNPCC), an algorithm was introduced to analyse and classify these two types of CRCs (Figure 
1.3). 
 
1.4.2.1. MSI analysis 
 
The National Cancer Institute (NCI) proposed five microsatellite markers essential to 
determine MSI presence: two mononucleotides, BAT25 and BAT26, and three dinucleotide 
repeats, D2S123, D5S346, and D17S250 (Odenthal et al., 2009). Tumours can therefore be 
classified into three groups: i.e. high MSI (MSI-H) if 2 or more markers are unstable, low MSI 
(MSI-L) when one marker shows instability and microsatellite stable (MSS) when none of the 
markers show instability. In addition, immunohistochemical (IHC) analysis of the MMR 
proteins is a supplementary approach used to determine MSI in CRC (Figure 1.3). Knowing 
the MSI status in CRC patients is useful in predicting some clinical behaviour e.g., prognosis 
and response to treatment, hence it is important to analyse the MSI status in this disease (Parc 
et al., 2004; Sinicrope et al., 2011). 
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Figure 1.  3: Algorithm for the workup of HNPCC and sporadic cancers using polymerase 
chain reaction (PCR) and IHC tests (Geiersbach and Samowitz, 2011). 
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1.4.3. Chromosomal instability 
 
Chromosomal instability (CIN) is a phenomenon where daughter cells receive an unequal 
number of DNA molecules and results in an unequal number of chromosomes during cell 
division (Orsetti et al., 2014). CIN occurs when the daughter cells do not have the same number 
of chromosomes as the cell they were derived from. CIN is seen in 65%–85% of sporadic 
colorectal cancers (Pino and Chung, 2010; Cisyk et al., 2015). It causes the loss of a wild-type 
copy of tumour suppressor genes, such as CDC4, P53, MYC, FGFR1, MRE11A, KRAS and 
SMAD4 (Mouradov et al., 2013; Ertych et al., 2014; Beyer et al., 2015; Cisyk et al., 2015).  
 
Furthermore, the two genetic instabilities i.e. MSI and CIN were suggested to have a joint role 
in the development and progression of colorectal cancer (Mouradov et al., 2013; Hveem et al., 
2014). There is a direct association between MSI/CIN positive tumours and stage II/III 
tumours, located on the right side of the colon. However, the tumours with MSI alone were 
associated with a better survival than those with CIN. In addition to the above mentioned 
genetic instabilities, colorectal carcinogenesis may also involve modifications in certain 
biological pathways involving microRNA and EMT (Mouradov et al., 2013; Hveem et al., 
2014).  
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1.5. Epigenetic factors: Changes in biological pathways 
 
MicroRNA (miRNA) and epithelial mesenchymal transition (EMT) play a significant role in 
key biological pathways linked with the development of cancer. MiRNAs are known to target 
and bind to the promoter regions of EMT-associated transcription factors (EMT-ATFs), thereby, 
down-regulating or up-regulating the expression levels of these TFs. Consequently, the down-
regulated or up-regulated expression of EMT-ATFs may promote CRC progression and certain 
clinical features e.g., invasion and metastasis of cancer cells (Pereira et al., 2015; Abba et al., 
2016).  
 
1.6. Biosynthesis of miRNAs  
 
MiRNAs are small non-coding molecules with about 20 to 22 nucleotides. These molecules 
are located in the introns and occupy about 2% to 5% of the human genome (Bullock et al., 
2012). They bind to their specific target messenger RNAs in the three prime un-translated (3ˊ 
UTR) region (Diaz-Lopez et al., 2014). These molecules regulate gene expression during 
developmental (embroyonic development), physiological (reproduction, fibrosis) and 
pathological (cancer development) processes (Chang and Hla, 2014). They are expressed as 
primary miRNAs (pri-miRNAs) in the nucleus and are processed by the RNase III enzyme 
(Drosha-DGCR8) to produce precursor miRNAs (pre-miRNA), (Figure 1.4). The pre-miRNA, 
with approximately 80 nucleotides then becomes translocated to the cytoplasm by the Exportin 
5 molecule (Figure 1.4) where it becomes cleaved by RNase III enzyme (Dicer), (Figure 1.4). 
This results in a mature miRNA of 21 to 22 nucleotides (Chen et al., 2014).  
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Figure 1.  4: miRNAs are processed by the RNase III enzyme (Drosha-DGCR8) in the 
nucleus to produce precursor miRNAs (pre-miRNA). The pre-miRNA then becomes 
translocated to the cytoplasm by the Exportin 5 molecule. In the cytoplasm, it is cleaved by 
another RNase III (Dicer) enzyme producing a mature miRNA. 
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1.7. Mechanisms of miRNA dysregulation in cancer 
 
MiRNA expression is regulated through various mechanisms, namely, transcriptional factors, 
epigenetic changes and genetic alterations (Croce, 2009; Chen et al., 2012). These mechanisms 
may contribute to the abnormal expression of miRNAs in human cancers (Deng et al.., 2008).  
 
MicroRNAs are known to directly regulate the expression of transcription factors at a post-
transcriptional level. The expression of a well characterized miRNA cluster, i.e., miRNA-17 to 
92a is activated by direct binding of c-MYC to its promoter region. Subsequently, these 
miRNAs suppress various targets, including cell cycle regulator p21 and pro-apoptotic factors, 
leading to increased chances of developing cancer. Similarly, miRNA-143 and miRNA-145 
which are significantly down-regulated in colorectal cancer are regulated by KRAS. Tumour 
suppressive miRNAs such as miRNA-34, miRNA-15a and miRNA-145 may also be regulated 
by transcription factors e.g., p53, EGFR, cMYC, MUC1 and SOX2 (Feng et al., 2011; 
Concepcion et al., 2012; Cui et al., 2014).  
 
DNA methylation and histone modification also form an important regulatory mechanism for 
miRNA regulation. In human cancers, miRNA promoter regions are known to be highly 
methylated. Down-regulation of tumour suppressor miRNAs, e.g., miRNA-34b and miRNA-
34c is mainly caused by hyper-methylation, seen in about 90% of primary CRCs (Majid et al., 
2012). Furthermore, genetic variations, including single nucleotide polymorphisms (SNPs), 
deletions and duplications also regulate miRNA expression. These variations are commonly 
seen in the mature sequence and 3’ UTR, leading to the removal of target recognition sites of 
miRNAs and hence loss of function (Meola et al., 2009).  
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1.8. miRNAs in cancer 
 
MiRNAs play an important role in the regulation of various metabolic and cellular pathways, 
particularly, cell proliferation, differentiation and survival (Faber et al., 2009). However, while 
regulating these cellular pathways, miRNAs can be abnormally expressed due to defects in the 
miRNA biosynthesis pathway and genetic alterations (e.g., mutations and chromosomal 
abnormalities), (Visone and Croce, 2009). MiRNAs have been classified as tumour suppressors 
or oncogenes (oncomirs), depending on the cancer and cellular environment in which they are 
expressed (Zhang et al., 2007). Tumour suppressor miRNAs (TS-miRNA) are down-regulated 
in cancer; they usually prevent cancer development by inhibiting oncogenes or genes that 
control cell proliferation and differentiation (Kent and Mendell, 2006). Oncogenic miRNAs 
(oncomirs), on the other hand, are up-regulated and therefore promote the development of 
cancer by stimulating cell proliferation (Shenouda and Alahari, 2009).  
In colorectal cancer, TS-miRNAs are commonly seen in patients who do not have lymph node 
metastasis, well differentiated tumours, early stages (I/II) and better prognosis, implying that 
TS-miRNAs play a role in preventing the progression of this cancer (Wiggins et al., 2010). 
Oncogenic miRNAs on the other hand, are associated with presence of lymph node metastasis, 
poorly differentiated tumours, advanced stages (III/IV) and poor prognosis of CRC, inferring 
that they drive or promote the progression of this disease (Zhang et al., 2007). MiRNAs also 
contribute to the development and progression of CRC by targeting and regulating biological 
pathways (e.g., EMT) involved in carcinogenesis (Hao et al., 2014). Investigating the 
expression profiles of tumour suppressor and oncogenic miRNAs may therefore be helpful in 
predicting progression and prognosis in individuals with CRC.  
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1.9. Epithelial mesenchymal transition (EMT) 
 
Epithelial-mesenchymal transition (EMT) is a biological process in which epithelial cells lose 
their cell-cell adhesion role and gain mesenchymal features i.e., invasion and migration 
properties (Yang and Weinberg, 2008). The EMT process is therefore characterized by a loss 
or down-regulation of epithelial proteins and increased expression of mesenchymal 
transcription proteins (Lee et al., 2006).  
 
1.10. EMT-associated transcription factors (EMT-ATFs) 
 
EMT is triggered and regulated by various EMT-ATFs, including the zinc-finger E-box-
binding homeobox (zeb), basic helix-loop-helix factors (Twist1 and Twist2) and snail family 
(snail1 and snail2) of zinc-finger transcription factors:. These transcription factors (TFs) 
recognize the E-box in the promoter region of E-cadherin, resulting in the gain of the 
mesenchymal phenotype i.e., N-cadherin and vimentin expression.  
 
1.10.1. Zeb 
 
Zeb is a zinc finger E-box-binding homeobox protein found in humans. It has two forms i.e. 
zeb-1 and zeb-2. Zeb-1 is encoded by the zeb-1 gene and is located in chromosome 10p11.2. 
Furthermore, zeb-2 is encoded by zeb-2 gene and is located in chromosome 2q22.3 
(Schmalhofer et al., 2009). The zeb protein connects with a transcription factor Brahma Related 
Gene1 (BRG1), in its N terminal region. This complex then binds to the E2 box of the CDH1 
gene promoter region. Once the zeb/BRG1 complex binds to the CDH1 E2 box, it changes the 
DNA structure, thereby suppressing the E-cadherin protein expression (Sanchez-Tillo et al., 
2010).  
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1.10.2. Twist 
 
Twist, also referred to as class A basic helix-loop-helix protein 38 (bHLH38) is encoded by the 
twist gene. This protein has two types, i.e., twist-1(located in chromosome 2p21.2) and twist-
2 (chromosome 2q37.3). The structure of twist is made up of two domains i.e. the C and N 
terminal domains (Barnes and Firulli, 2009). The N terminal region has a basic domain with 
amino acids that bind to the E box of CDH1 (Margetts, 2012), whilst the C terminal region has 
the HLH domain which attaches to other proteins to form complexes. These proteins also have 
2 α-helices in their structure, one in the C terminal region and another in the N terminal region 
(Jones, 2004).  
 
1.10.3. Snail 
 
Snail belongs to a family of basic helix-loop-helix (bHLH) transcription factors which regulate 
neural crest development and tumour invasion (Zavadil et al, 2008). The snail family has three 
members i.e. snail-1 (chromosome 20q13.13), snail-2 also known as slug (chromosome 8q11) 
and snail-3 (chromosome 16q24.3). These proteins interact with various EMT factors such as 
claudins, sox9 and fosd3. Snail-1 and snail-2 are significant regulators of EMT. They act by 
repressing E-cadherin expression, resulting in the up-regulation of N-cadherin protein. Their 
structure consists of C terminal, N terminal and Snag domains (Figure 1.5). The N terminal 
region is important for the transcriptional repressor activity. Snail-1 has a regulatory domain 
that has a nuclear export signal and a destructive box domain. However, snail-2 has a slug 
domain which mediates repression of epithelial proteins (Villarejo et al., 2014).  
 
Furthermore, the C terminal region of snail-1 and snail-2 proteins consists of a DNA-binding 
domain (DBD), which identifies and binds to the E2-box of CDH1. The DBD has 4 to 6 zinc 
fingers (ZFs) consisting of short tandem repeats with 22 to 25 amino acids. Snail-1 has 4 ZFs 
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(ZF1-ZF4) and snail-2 5 ZFs (ZF1-ZF5). These ZFs have different interactions and affinities 
to their target genes (Villarejo et al., 2014). Snail-1 and snail-2 decrease E-cadherin expression 
by binding to the E2 box promoter region of CDH1. The snail-1 protein uses ZF1 and ZF2, 
while snail-2 uses ZF3 and ZF4 to bind to the E2 box of E-cadherin, causing promoter 
repression. After having bound to the CDH1 promoter, the snag domain of snail-1 recruits 
another complex of co-repressors consisting of histone deacetylase 1 and 2 (HDAC1 and 
HDAC2) and sin3A (Molina-Ortiz et al., 2012). Snail-1 and Snail-2 also trigger the expression 
of mesenchymal molecules e.g. vimentin, fibronectin and N-cadherin. (Peinado et al., 2004).  
 
 
 
 
Figure 1.  5: Snail-1 and snail-2 structure consists of C terminal, N terminal and Snag 
domains. Snail-1 has a regulatory domain that has a nuclear export signal (NES) and a 
destructive box domain. Snail-2 has a slug domain which mediates repression of epithelial 
proteins. These proteins use the Zinc Finger (ZF) structures to bind to E-cadherin E2 box 
(Molina-Ortiz et al., 2012). 
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1.10.4. Vimentin 
 
Vimentin is a type III intermediate filament (IF) molecule and is expressed in the cytoskeleton 
of mesenchymal cells. It is therefore a marker of cells going through the epithelial-
mesenchymal transition process (Cabeen and Jacobs-Wagner, 2010). This protein provides 
stability and support to organelles in the cytosol. It also functions to sustain the cell shape and 
integrity of the cytoplasm. Another important function of this molecule is that it mediates cell 
adhesion and migration (Ivaska et al., 2007). Vimentin has three regions, namely, the non-
helical amino-terminal, carboxy-terminal (tail) and α-terminal (rod) domains. The amino-
terminal and carboxy-terminal make up the features of each IF molecule (Ivaska et al., 2007). 
The α-terminal domain has 330 amino acids and is vital for the organization of intermediate 
filaments (Ivaska et al., 2007; Herrmann et al., 1996).  
 
1.10.5. N-cadherin 
 
N-cadherin is a neural classical cadherin (N-cadherin) protein which is encoded by the CDH2 
gene. N-cadherin is a transmembrane protein with three domains, namely, the extracellular, 
intracellular and cytoplasmic domains (Walsh et al., 1990). The extracellular domain has five 
cadherin repeats (Figure 1.6), each with N and C termini. N-cadherin protein functions to 
mediate cell-cell adhesion in different tissues. N-Cadherin expression is commonly associated 
with invasion and migration of cancer cells (Araki et al., 2011).  
 
 
Figure 1.  6: N-cadherin protein showing extracellular, membrane and intracellular domains. 
The extracellular domain has five cadherin repeats, each with N and C termini. 
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1.10.6. E-cadherin 
 
Epithelial (E) cadherin is a cell-cell adhesion type 1 classical transmembrane protein which is 
encoded by the CDH1 gene. E-cadherin is located in the adherence junctions and has three 
domains, namely, the extracellular, intracellular and cytoplasmic domains (Shapiro and Weis, 
2009). The extracellular domain has five cadherin repeats (Figure 1.7), each with N and C 
termini. In between these repeats are four calcium binding sites where calcium ions (Figure 
1.7) bind (Boggon et al., 2002). These calcium ions regulate E-cadheirn function and also 
protect the protein from degradation (Cailliez and Lavery, 2005).  The E-cadherin protein binds 
with various catenin molecules, namely, p120-catenin, α-catenin, γ-catenin and β-cateninin in 
the cytoplasmic domain to maintain cell stability (Aberle et al., 1996).  
 
 
 
 
Figure 1.  7: A diagrammatic representation of the E-cadherin protein showing extracellular, 
transmembrane and cytoplasmic domains.  E-cadherin binds with p120-catenin, α-catenin, γ-
catenin and β-catenin molecules in the cytoplasmic domain (Aberle et al., 1996). 
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1.11. Cancer stem cell markers 
 
Research has reported that a subgroup of cancer cells, called cancer stem cells (CSC) have the 
ability to stimulate cancer. CSCs were first identified in the hematopoietic model and have 
been reported to play a role in the development of various cancers, including colorectal cancer. 
Colorectal CSCs (CCSC) have been classified using CD44 or CD133 either alone or together 
with other markers, such as EpCAM, CD166, CD29, CD24, LGR5 and aldehyde 
dehydrogenase1 (ALDH1). Earlier studies have shown that CCSCs may trigger the 
development of CRC and that CD44 is one of the most imperative biomarkers of CCSCs.  
 
Importantly, latest studies have demonstrated a link between EMT and CSC properties. This is 
supported by the expression of the EMT-markers (snail-1/snail-2 and twist) in CSC that are 
involved in the loss of the epithelial phenotype and the acquisition of the mesenchymal 
phenotype. A summary of markers which play roles in EMT and CSC phenotype is shown in 
Table 1.1. Stem cell markers, i.e., CD44v6, CD44v9, CD123 and CD133 have been shown to 
regulate the EMT process in CRC (Fan et al., 2012; Du et al., 2013; Mashita et al., 2014; Saito 
et al., 2013). These studies showed an inverse relationship between expression levels of the 
above mentioned stem cell markers and E-cadherin (Saito et al., 2013; Mashita et al., 2014). In 
addition, there was an association between increased expression of the stem cell markers and 
mesenchymal markers (N-cadherin, vimentin, twist and snail), (Fan et al., 2012; Due et al., 
2013; Mashita et al., 2014). These investigations suggested that the CCSC phenotype is 
correlated with the EMT phenotype in CRC.  
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Table 1. 1: Various molecules connecting EMT and CSC phenotype 
  
Name Function Reference 
CD44 and 
CD44v6  
 
CSC markers, play a role in migration, invasion and EMT  
 
Du et al., 2013 
Saito et al., 2013 
CD133  
 
CSC and EMT marker   
 
Fan et al., 2012 
Snail-1/2  
 
Involved in invasion, migration and EMT process 
 
Fan et al., 2012 
Twist  
 
EMT, invasion, migration and metastasis 
 
Escobar-Cabrera et 
al., 2013 
Vimentin  
 
Biomarker of CSC and EMT features 
 
Mashita et al., 2014 
Twist  
 
EMT, invasion, migration and metastasis 
 
Escobar-Cabrera et 
al., 2013 
Vimentin  
 
CSC and EMT phenotypes 
 
Mashita et al., 2014 
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1.12. miRNAs and EMT in CRC: Overview 
 
EMT-ATFs are classified into epithelial (e.g. E-cadherin) and mesenchymal transcription 
factors (TFs) e.g., snail, twist and zeb. These TFs activate the EMT process by binding to the 
promoter region of E-cadherin, resulting in the loss or down-regulated E-cadherin expression. 
In addition, the TFs stimulate expression of proteins associated with the mesenchymal 
phenotype, namely, N-cadherin and vimentin. Loss of the epithelial (down-regulated E-
cadherin) and gain of the mesenenchymal phenotype (up-regulated N-cadherin and vimentin) 
is associated with sinister clinicopathologic features (e.g., presence of lymph node metastasis, 
poor differentiation, advanced stages and poor survival), suggesting that EMT plays a role in 
the progression of the disease (Fan et al., 2013; Findlay et al., 2013; Kroepil et al., 2013; 
Toiyama et al., 2013).  
 
 
In addition, miRNAs regulate the EMT process by either inhibiting or promoting the expression 
levels of EMT-ATFs. During carcinogenesis, miRNAs bind to the UTR regions of these TFs. 
After the miRNAs bind to the TFs, they either reverse or promote the EMT process, depending 
on the type of miRNAs (Song et al., 2013; Tanaka et al., 2013). Tumour suppressor miRNAs 
reverse the EMT process by suppressing the expression of mesenchymal transcription factors. 
This then leads to cells regaining the epithelial phenotype, which is shown by the expression 
of E-cadherin (Hur et al., 2013; Long et al., 2013, Paterson 2013). On the other hand, oncomirs 
promote and drive the EMT process by inducing the expression of mesenchymal transcription 
factors. In addition, oncomirs down-regulate E-cadherin expression by targeting CDH1 (Xiong 
et al., 2013; Yu et al., 2013).   
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1.12.1. Tumour suppressor miRNAs 
 
Tumour suppressor miRNAs are commonly known to promote the epithelial phenotype in CRC 
by targeting and suppressing mesenchymal transcription factors. This implies that high 
expression of TS-miRNAs is associated with up-regulated E-cadherin and down-regulated 
expression of mesenchymal factors. This indicates that TS-miRNAs are inhibitors of EMT, 
suggesting their role in preventing tumour development and progression. The most frequently 
investigated TS-miRNAs in cancer are the miRNA-200 and miRNA-34 families.  
 
1.12.1.1. miRNA-200 family 
 
The miRNA-200 family consists of five molecules: miRNA-200a, miRNA-200b, miRNA-
200c, miRNA-141 and miRNA-429 (Ahmad et al., 2011; Uhlamann et al., 2010).  Four of the 
miRNA-200 family members (i.e., miRNA-200a, miRNA-200b, miRNA-200c and miRNA-
141) have been shown to have an inverse relationship with N-cadherin, vimentin, Twist2, Zeb1 
and Zeb2 in CRC (Long et al., 2013; Paterson et al., 2013; Hur et al., 2013).  These miRNA-
200 members repress the expression levels of these factors, thereby reversing EMT. Reversing 
the EMT process is an indication that the epithelial phenotype (increased E-cadherin 
expression) is promoted while the mesenchymal phenotype is inhibited (Long et al., 2013; 
Paterson et al., 2013; Hur et al., 2013). Two (miRNA-200c and miRNA-141) of the miRNA-
200 family do not act as tumour suppressors; but rather as oncogenes, since they were shown 
to be up-regulated in liver metastases of CRC compared to the primary tumours (Hur et al., 
2013). Therefore, further research is needed to determine whether miRNA-200c and miRNA-
141 act as tumour suppressors or oncogenes in this tumour. 
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1.12.1.2. miRNA-34 family 
 
MiRNA-34 family consists of three members i.e. miRNA-34a, miRNA-34b and miRNA-34c. 
Amongst this family, miRNA-34a which is located in chromosome 1p36 is the most commonly 
investigated member in CRC. MiRNA-34a targets numerous transcription factors (e.g., 
oncogenes and cancer stem cell markers) including CD44, CDK4, CDK6, c-Met, Notch-1, 
Notch-2, SIRT1 and DLL1 (Saito et al., 2015). Several studies (Nugent et al., 2012; Aherne et 
al., 2014; Ma et al., 2014) measured miRNA-34a expression levels in CRC. In addition, they 
observed an association between miRNA-34a and clinicopathologic features (Nugent et al., 
2012; Ma et al., 2014). The expression pattern of miRNA-34a in CRC has been controversial. 
While some studies observed low expression, others observed high expression of miRNA-34a 
in the tumour compared to normal tissue. The majority of these studies observed that miRNA-
34a expression levels were associated with better prognosis, decreased cancer cell growth, 
migration, invasion and metastasis in CRC. However, Nugent et al (2012) did not observe any 
association between miRNA-34a expression levels and clinicopathologic features.   
 
Furthermore, there have only been two investigations that determined the relationship between 
miRNA-34a expression levels and EMT in CRC. MiRNA-34a expression levels were 
measured in cell lines (HK-2, SW480 and SW620) with EMT features, i.e., increased snail, 
zeb1, vimentin and decreased E-cadherin expression. These studies showed an inverse 
relationship between miRNA-34a expression levels and mesenchymal transcription factors in 
CRC cells lines (Du et al., 2012; Rokavec et al., 2014).  
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1.12.2. Oncogenic miRNAs (Oncomirs) 
 
Research has shown that over-expressed miRNAs can down-regulate a tumour suppressor or 
up-regulate genes involved in cell differentiation and proliferation, thereby promoting the 
development of cancer. These kinds of miRNAs are said to act as oncogenes (Zhang et al., 
2007). Increased expression of oncomirs is associated with up-regulated expression of 
mesenchymal transcription proteins, implying that these miRNAs stimulate EMT. 
Additionally, up-regulated oncomirs are indicative of an aggressive disease and poor prognosis. 
The most frequently investigated oncomirs in cancer studies are miRNA-155 and miRNA-21.  
 
1.12.2.1. miRNA-155 
 
Two investigations showed high expression levels of miRNA-155 in CRC tissues compared 
with normal tissues. In addition, high miRNA-155 expression levels were associated with 
presence of lymph node metastasis, distant metastasis, poor differentiation, advanced stages 
and poor survival in CRC. High miRNA-155 expression levels were also linked with increased 
proliferation, migration and invasion characteristics in CRC cell lines i.e., SW480 and HT-29 
(Zhang et al., 2013; Qu et al., 2015). These results infer that high miRNA-155 expression is of 
clinical significance and is associated with progressive CRC. Therefore, miRNA155 can be 
used to predict clinical and pathological features (e.g., lymph node metastasis and prognosis) 
in CRC.  
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1.12.2.2. miRNA-21 
 
MiRNA-21 (miRNA-21) was one of the first miRNAs to be defined as an oncogene. It is 
encoded by TMEM49 gene in chromosome 17q23-1. It is one of the most important miRNAs 
associated with the development and progression of different human cancers. MiRNA-21 
targets various transcription factors (oncogenes and tumour suppressor genes), therefore 
causing cell migration, invasion and metastasis. These genes include programmed cell death 4 
(PDCD4), phosphatase and tensin homolog (PTEN), Cell division cycle 25 homolog A 
(Cdc25a), reversion-inducing-cysteine-rich protein with kazal motifs (RECK), TIMP3, 
maspin, nuclear factor 1 B-type (NFIB), tropomyosin 1 (TPM1), sprouty 2 (SPRY2), T-
lymphoma invasion and metastasis-inducing protein 1 (TIAM1), and Ras homolog gene 
family, member B (RHOB) (Meng et al., 2007; Zhu et al., 2008; Asangani et al., 2008; Lu et 
al., 2008; Sayed et al., 2008; Cottonham et al., 2010; Liu et al., 2011; Xiong et al., 2013; Yang 
et al., 2015).  
 
Xiong et al (2013) and Yang et al (2015) determined the expression of miRNA-21 and the 
regulatory role of PTEN protein in CRC tissues. These studies showed that inhibition of 
miRNA-21 resulted in increased PTEN expression. In addition, down-regulated PTEN and up-
regulated miRNA-21 expression were associated with an aggressive behaviour of the cancer.  
 
Other investigations measured miRNA-21 expression levels and determined its relationship 
with the clinicopathologic features of the tumour (Nielsen et al 2011; Kjaer-Frifeldt et al., 2012; 
Toiyama et al., 2012; Xiong et al., 2013; Bullock et al., 2014; Yang et al., 2015) in CRC. These 
studies showed that high miRNA-21 expression levels were associated with invasion of tumour 
cells, poor differentiation, presence of lymph node metastasis and stages III/IV of the cancer. 
This suggests that miRNA-21 plays a role in the progression of the disease.  
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The studies by Nielsen et al (2011); Kjaer-Frifeldt et al (2012) and Toiyama et al., 2012 showed 
an association between increased miRNA-21 expression levels and decreased recurrence free 
cancer survival, suggesting the prognostic significance of miRNA-21. In addition, Nielson and 
Toiyama also observed an association between miRNA-21 expression and overall survival.  
 
Another finding by Toiyama et al (2012) is that miRNA-21 also serves as a prognostic and 
predictive biomarker for response to chemotherapy in CRC. These data are consistent with two 
previous studies (Schetter et al., 2008 and Valeri et al., 2010). In addition, miRNA-21 
expression is associated with therapeutic outcome to 5FU-based therapies. Valeri et al (2010) 
also showed that miRNA-21 induced resistance to 5FU in colon cancer cell lines by down 
regulating the expression of DNA repair protein MutS homolog 2 (MSH2). These 
investigations support the conclusion that miRNA-21 is up-regulated in colorectal cancer and 
that its high expression level is associated with advanced and aggressive clinical behaviour of 
the tumour.  
 
Thus far, only two studies have examined the relationship between miRNA-21 expression 
levels and EMT in CRC. These investigations included CRC cell lines (Caco-H2, HCT116, 
Colo-205, Caco-2 and RKO cells) with EMT features (down-regulated E-cadherin protein and 
up-regulated N-cadherin/vimentin expression). MiRNA-21 expression levels were also 
measured in the cell lines which did not have EMT features. There were high miRNA-21 
expression levels in the cell lines with EMT features compared to the cell lines with no EMT. 
These results inferred that this oncomir (miRNA-21) activates the EMT process, thus 
contributing to the progression of CRC. 
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1.13. Rationale for the study 
 
EMT is regulated by miRNAs that either function as tumour suppressors or oncogenes 
(oncomirs). Tumour suppressor miRNAs reverse EMT while oncomirs activate it. Therefore, 
identifying how miRNAs regulate the EMT process is important in addressing the progression 
of CRC. This study will focus on investigating the expression levels of miRNA-21 and 
miRNA-34a in relation to the EMT phenotype. These two miRNAs are investigated since they 
are commonly de-regulated in cancer and said to function co-operatively (Hashimi et al., 2009; 
Sun et al., 2013; Ma et al., 2014). Since there has not been any study conducted on the role of 
miRNA and EMT in colorectal cancers in South Africa, we carried out an investigation to 
determine if there was a relationship between these parameters in our population cohort. The 
aim of this study was to evaluate the relationship between miRNAs (miRNA-21 and miRNA-
34a) and EMT markers in colorectal cancer cases seen in the Western Cape. In addition, this 
investigation aimed to correlate miRNA and EMT data with clinicopathologic features in order 
to determine if the two miRNAs can be used as potential biomarkers to monitor progression.  
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The objectives of this study are to: 
1. Classify EMT positive (high expression of mesenchymal transcription factors) and 
EMT negative (high expression of the epithelial protein) CRC cases using IHC. 
2. Correlate the expression levels of mesenchymal markers (N-cadherin, vimentin and 
snail1) and a stem cell marker (CD44v6) with the epithelial protein (E-cadherin) in 
CRC cases. 
3. Quantify the expression levels of two miRNAs (miRNA-21 and miRNA-34a) in EMT 
positive and EMT negative tumours, using qRT-PCR. Subsequently, correlate the 
miRNA and EMT data with the demographic and clinicopathologic data of the cases. 
 
1.14. Hypothesis 
 
MiRNA-21 and miRNA-34a regulate the expression of EMT-associated transcription factors 
(E-cadherin, N-cadherin, vimentin and snail) and thus contribute to CRC progression. 
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Chapter Two 
 
2. Materials and Methods 
 
2.1. Ethics Approval 
Ethics approval for the project was obtained from the Human Research Ethics Committee, 
Faculty of Health Sciences (HREC REF: 250/2014), at the University of Cape Town. 
 
2.2. Sample size determination 
A statistician was consulted and the sample size was determined using the Power and Sample 
Size Program (PSSP). The number of cases selected was based on the worldwide proportion of 
the EMT markers expressed in colorectal cancer (Table 2.1); the acceptable power level was 
set at 80%.  
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Table 2. 1: Sample size and power determination using the proportion of E-cadherin, snail-1 
and twist expressed in CRC tissue, worldwide.   
EMT 
marker* 
Sample 
size (n) 
 
EMT + 
Proportion 
(%) 
EMT-
Proportion 
(%) 
E-cad – 
Repressed$ 
(%) 
E-cad + 
Expressed 
(%) 
Power 
(%) 
Snail-1 50 75% 25% 87% 39% 82% 
45 75% 25% 87% 39% 78% 
30 75% 25% 87% 39% 24% 
Twist 50 73% 27% 51% 23% 22% 
45 73% 27% 51% 23% 20% 
30 73% 27% 51% 23% 12% 
*Snail-2 was not used to calculate power and sample size due to the low expression level of 
37% in CRC tissues (Shioiri 2006). 
$ The expression level of E-cadherin protein does not add up to 100% as the expression is based 
on a scoring system. 
 
2.2.1. Sample collection  
 
One hundred formalin fixed paraffin embedded (FFPE) colorectal cancer tissue blocks and 
their corresponding Haematoxylin and Eosin (H&E) slides were collected from the archives of 
the Division of Anatomical Pathology, UCT/NHLS. The H & E slides were reviewed by a 
pathologist (ML) and tissue blocks containing tumour and normal regions were selected. These 
cases included 8 HNPCCs i.e., those which were positive for MLH1 germline mutations. The 
data related to these HNPCCs were obtained from the Division of Human Genetics, University 
of Cape Town.  
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2.3. Immunohistochemical staining of CRC cases 
Immunohistochemistry was performed to determine the expression levels of EMT transcription 
factors: E-cadherin, N-cadherin, vimentin, snail-1 and CD44v6 (stem cell marker). The FFPE 
tissue blocks were sectioned at 3μm and picked up on coated glass slides (Histobond, 
Marienfeld). The 3μm tissue sections were then placed and left on a hot plate for 15 minutes 
to melt the wax. Subsequently, the tissue sections were incubated in 3 washes of xylene baths 
for 5 minutes each, to dissolve and remove wax. After dewaxing in xylene, they were incubated 
in 3 washes of absolute alcohol for 5 minutes each, to clear the xylene. Following the clearing 
process, the tissue sections were hydrated in tap water for 5 minutes. Antigen retrieval was then 
performed for 1 minute 30 seconds at full pressure using the appropriate retrieval buffer (Table 
2.2). The tissue sections were incubated with 3% hydrogen peroxide (3% H2O2) for 10 minutes 
to block endogenous peroxidase activity. Subsequently, the tissue sections were washed in 10x 
phosphate buffered saline (PBS)-tween for 10 minutes to remove the blocking agent. After 
washing with PBS, the tissue sections were incubated with 5% normal goat serum (NGS) for 
20 minutes to block background and nonspecific staining during antibody application. The 
tissue sections were then stained with the respective primary antibodies which were diluted and 
incubated as per Table 2.2. A positive control was added to each staining batch and a negative 
reagent control in which the primary antibody was replaced with 5% NGS was also included. 
Subsequent to the primary antibody incubation, a secondary polymer antibody was applied on 
the sections for 30 minutes at room temperature. Following secondary antibody incubation, the 
sections were washed in 10x PBS-tween for 5 minutes and 3,3’-diaminobenzidine (DAB) 
chromogen was applied for 10 minutes to visualize the staining. The sections were then 
counterstained with Mayer’s haematoxylin, mounted with cover slips and analysed under a 
microscope.   
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Table 2. 2: Antibodies used to determine EMT status in 100 CRC cases. 
Antibody Clone Species Supplier Dilution Incubation 
time 
Antigen 
retrieval 
Positive 
control 
E-cadherin 36B5 Monoclonal-
mouse 
Novacastra 1:20 1 hour EDTA, 
pH8 
Prostate 
N-cadherin IAR06 Monoclonal-
mouse 
Leica 1:100 30 minutes Tris/EDTA Testis  
Vimentin CloneV9 Monoclonal-
mouse 
Dako 1:600 30 minutes Tris/EDTA Sarcoma 
Snail-1 Ab180714 Polyclonal-
rabbit 
Abcam 1:50 Overnight 
4 ºC 
EDTA, 
pH8 
Testis 
CD44v6 
(Stem cell) 
VFF-7 Monoclonal-
mouse 
Leica 1:50 1 hour EDTA, 
Ph8 
Tonsil  
 
2.4. Immunohistochemical evaluation of EMT transcription factors 
All the stains were evaluated together with a pathologist (M.L) and a consensus was reached 
on each case. It is therefore possible that there could be intra or inter observer variability. It 
was not possible for more people to review all the stains. 
 
2.4.1. E-cadherin, N-cadherin and vimentin 
E-cadherin expression was scored as either positive or negative. Negative expression was 
defined as less than 70% membranous staining of tumour cells. Positive expression, on the 
other hand, was defined as 70% or greater membranous staining of tumour cells. The E-
cadherin scoring method was adopted from a previous study (Rubin et al., 2001). N-cadherin 
was scored based on the proportion of cancer cells staining; staining of < 20% of tumour cells 
indicated low expression and staining of ≥ 20% tumour cells indicated high expression 
(Nakajima et al., 2004). Moreover, membranous or cytoplasmic staining of vimentin in > 5% 
tumour cells was considered positive expression (Fan et al., 2013).  
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2.4.2. Snail-1 
A semi-quantitative method was used to score snail-1. The percentage (0 to 100%) and 
predominant staining intensity (0 to 3) of tumour cell nuclei were analysed. The score was 
attained by multiplying the proportion and intensity values. A score of < 10/300 indicated 
negative expression of snail-1 and a score of ≥ 10/300 showed positive expression (Franci et 
al., 2009).  
 
2.4.3. CD44v6 
CD44v6 membrane staining of ≥ 10% tumour cells was considered positive expression (Saito 
et al., 2013).   
 
2.5. Relationship between EMT markers and clinicopathologic features 
 
The EMT and stem cell markers were correlated with clinicopathologic features of the tumour 
using Fisher’s Exact and Pearson Chi Square tests in Stata 12. In addition, the relationship 
between E-cadherin and mesenchymal/stem cell markers (N-cadherin, vimentin, snail-1 and 
CD44v6) was determined using the same tests.  
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2.6. miRNA analysis 
 
2.6.1. Case selection  
 
Various studies have shown that a minimum sample size of 21 to 30 cases is sufficient for 
conducting miRNA analysis (Rentolf et al., 2011; Du et al., 2012; Xiong et al., 2013). 
Therefore, our study included 59 CRC cases (8 of which were HNPCCs) to quantity miRNA-
21 and miRNA-34a expression levels. H&E slides were examined by a pathologist to 
demarcate normal and tumour regions. Subsequently, corresponding FFPE tissue blocks were 
sectioned at 10μm and fixed on Histobond glass slides. These 10μm sections were then 
dewaxed in xylene, washed in running tap water and allowed to dry at room temperature. After 
the sections had dried, they were superimposed onto the demarcated H & E slides, to mark off 
normal and tumour regions. Fifty nine tumour and 12 normal (uninvolved mucosa randomly 
selected as controls), (Aherne et al., 2014) sections were then scraped off and transferred into 
different 1.5ml Eppendorf tubes.  
 
2.6.2. RNA Isolation from the 59 cases   
Following scraping, RNA isolation was carried out using a High Pure FFPET RNA isolation 
Kit (Roche), according to the manufacturer's instructions. The protocol involved adding 100µl 
of RNA Tissue Lysis Buffer into the 1.5ml Eppendorf tubes containing the tissue sections. The 
Lysis buffer was added in order to rupture the cell membrane. Following that step, 16µl of 10% 
SDS and 16µl proteinase K were added to inactivate and remove any nucleases that might 
degenerate the RNA. After adding these reagents, the Eppendorf tubes were vortexed and 
briefly spun down at 600 rpm using a centrifuge. These Eppendorf tubes were then incubated 
in a water bath at 85°C for 30 minutes. Following the incubation period, 80µl of proteinase K 
was added onto the Eppendorf tubes which were then vortexed briefly. The sections were 
incubated again at 55°C for 30 minutes. After the second incubation period, a volume of 325µl 
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RNA binding buffer used to bind RNA and 325µl absolute alcohol (used to remove 
contaminants from the solution) were added to the tissue lysates. The lysates in the 1.5ml 
Eppendorf tubes were then briefly vortexed at 600 rpm and transferred into High Pure Filter 
tubes placed onto High Pure collection tubes. The tubes were then centrifuged for 30 minutes 
at 6, 000 xg and the flow through discarded. High Pure Filter tubes were then placed onto new 
High Pure Collection tubes and centrifuged at 16, 000 xg to dry the filter completely. The High 
Pure Filter tubes were again placed onto new collection tubes and 100µl of DNase solution 
used to digest residual DNA was added without touching the fleece of the filters. The High 
Pure Filter tubes were then incubated at room temperature for 15 minutes. Thereafter, a volume 
of 500µl of wash buffer I was added to the High Pure Filter tubes and then centrifuged at 6, 
000 xg for 20 seconds. The flow through was discarded and 500µl wash buffer II added to the 
High Pure Filter tubes. Subsequently, the tubes were centrifuged at 6, 000 xg for 20 seconds 
and the flow through was discarded. The tubes were then centrifuged at 16, 000 xg for 2 
minutes. After centrifugation, the High Pure Filter tubes were placed in new 1.5 ml autoclaved 
Eppendorf tubes and 30µl of RNA Elution buffer added to the centre of the filter tube without 
touching the fleece. The Eppendorf tubes were then incubated at room temperature and 
centrifuged at 6, 000 xg for a minute. The RNA in the Eppendorf tubes was then stored at -
20°C. 
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2.6.3. RNA quantification and poly A reaction 
The RNA samples were quantified in a Nanodrop (Thermo Scientific, Wellington, DE 19810 
USA) instrument using a volume of 2µl. The samples were then diluted to 100ng and Poly A 
reaction was carried out in a final volume of 20µl consisting of template RNA (100ng); 5 x 
PAP buffer; 25mM MnCl2; 100mM ATP; nuclease free water and 2U/µl of Poly (A) 
polymerase. A negative control (nuclease free water instead of RNA) was included in the 
reaction. The PCR conditions used were 37°C for 75 minutes and 65°C for 25 minutes. 
  
2.6.4. cDNA synthesis 
Subsequent to the poly A reaction, cDNA was synthesized in a final volume of 20µl using 
100ng Poly A product, dH2O, 10mM dNTPs, 5x transcription reverse transcriptase reaction 
buffer, 25mM MgCl2, 40U/µl protector RNase inhibitor, 20U/µl transcriptor reverse 
transcriptase and 50mM adaptors. The PCR conditions were as follows: 
 42°C for 60 minutes 
 42°C for 75 minutes  
 85°C for 10 minutes 
 The cDNA products were then diluted to 1000ng and stored at -20°C. 
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2.6.5. miRNA-21 and miRNA-34a quantitative Reverse Transcriptase-Polymerase 
Chain Reaction (qRT-PCR)  
A master mix was prepared using 2x Sybrgreen (KapaBiosystems), dH2O and 10µM of the 
primers (Table 2.4) for miRNA-21, miRNA-34a and 18S (18S and normal tissues were used to 
normalise miRNA expression in each tumour sample) in separate Eppendorf tubes. The 
Eppendorf tubes were then briefly vortexed and a volume of 19.3µl from each master mix was 
added onto 96 well plates (Table 2.5 and Table 2.6). Subsequently, a volume of 0.7µl cDNA 
(1000ng) from each of the samples (e.g. 1 to 15 tumour samples) was added onto the 19.3µl 
master mix (Table 2.5 and Table 2.6) in triplicates. A blank (B), in which sterile water was 
added instead of cDNA was included to normalise the reaction. The 96 well plates were then 
covered with adhesive sealing films to prevent evaporation, leakage and contamination 
between the wells. The plates were then centrifuged at high speed and placed in a Light 
Cycler480® instrument (Roche) to perform the qRT-PCR (Table 2.3). The qRT-PCR was 
performed twice to verify the quantitative data generated by the instrument. 
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Table 2. 3: The qRT-PCR conditions for miRNA-21 and miRNA-34a. 
Stage Number of 
cycles 
Temperature (°C) Time  Ramp (°C/s) 
Pre-incubation 1 cycle 95 5 m 4.4 
Amplification 45 cycles 95 (Denaturation) 10s 4.4 
60 (Annealing) 15s 2.2 
72 (Extension) 5s 4.4 
Melting curve 1 cycle 95 5s 4.4 
65 1s 2.2 
97 Continuous 0.11 
Cooling 1 cycle 40 30s 2.2 
  
 
 
Table 2. 4: All the primers were synthesised at Molecular Cell Biology (MCB), UCT. 
Molecule Forward primer Reverse primer 
miRNA-
21 
AACACCAGTCGATGGGTC GGTCCAGTTTTTTTTTTTTTTTTACA 
miRNA-
34a 
AGTGGCAGTGTCTTAGCTGG AGGGTCCAGTTTTTTTTTTTTT 
18S TTTCGCTCTGGTCCGTCTTG TTCGGAACTGAGGCCATGAT 
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Table 2. 5: A representation of miRNA-21 qRT-PCR performed twice in a 96 well plate. 
    Sample 1 to 15       
Master 
mix   1 2 3 4 5 6 7 8 9 10 11 12 
miRNA-21 A 1 1 1 2 2 2 3 3 3 4 4 4 
18S B 1 1 1 2 2 2 3 3 3 4 4 4 
miRNA-21 C 5 5 5 6 6 6 7 7 7 8 8 8 
18S D 5 5 5 6 6 6 7 7 7 8 8 8 
miRNA-21 E 9 9 9 10 10 10 11 11 11 12 12 12 
18S F 9 9 9 10 10 10 11 11 11 12 12 12 
miRNA-21 G 13 13 13 14 14 14 15 15 15 B B B 
18S H 13 13 13 14 14 14 15 15 15 B B B 
   
 
  
 
Table 2. 6: A representation of miRNA-34a qRT-PCR performed twice in a 96 well plate 
    Sample 1 to 15       
Master 
mix   1 2 3 4 5 6 7 8 9 10 11 12 
miRNA-
34a A 1 1 1 2 2 2 3 3 3 4 4 4 
18S B 1 1 1 2 2 2 3 3 3 4 4 4 
miRNA-
34a C 5 5 5 6 6 6 7 7 7 8 8 8 
18S D 5 5 5 6 6 6 7 7 7 8 8 8 
miRNA-
34a E 9 9 9 10 10 10 11 11 11 12 12 12 
18S F 9 9 9 10 10 10 11 11 11 12 12 12 
miRNA-
34a G 13 13 13 14 14 14 15 15 15 B B B 
18S H 13 13 13 14 14 14 15 15 15 B B B 
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2.7. Significance of miRNA-21 and miRNA-34a in MSI 
 
The clinical significance of miRNA-21 and miRNA-34a were assessed taking into account the 
microsatellite instability (MSI) status.  
 
2.7.1. Determining microsatellite instability (MSI) using IHC 
 
 
IHC staining for MLH1, MSH2 and MSH6 mismatch repair (MMR) proteins (Table 2.7) was 
performed on the Ventana platform (Ventana Benchmark XT) to distinguish between 
microsatellite stable (MSS) and microsatellite unstable (MSI) tumours. Cases were evaluated 
for MLH1, MSH2 and MSH6. Those with nuclear staining in normal and cancerous colon 
epithelium were classified as MSS. Moreover, cases with a negative protein expression were 
classified as MSI. 
 
Table 2. 7: MMR antibodies used to determine MSI status in 59 CRC cases 
Antibody Clone Species Supplier Dilution Incubation Antigen 
retrieval 
Positive 
control 
MLH1 M1 Monoclonal-
mouse 
Ventana Pre-
diluted 
Platform Platform Lymph node 
MSH2 G219-1129 Monoclonal-
mouse 
Cell 
Marque 
Pre-
diluted 
Platform Platform Lymph node 
MSH6 44 Monoclonal-
mouse 
Ventana Pre-
diluted 
Platform Platform Lymph node 
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2.8. Statistical analysis 
 
The relative quantification method was used to determine the expression levels of miRNA-21 
and miRNA-34a in the tumour relative to the normal (Shi and Chiang, 2005). The expression 
levels were represented as 2-∆∆Ct values = (Ct tumour – Ct normal miRNA) - (Ct tumour – Ct normal 18S) 
(Appendices D and E). MiRNA-21 and miRNA-34a expression levels were determined for 
EMT markers, clinicopathologic features (stage, grade, lymph nodes metastasis and tumour 
site), MSI and MSS tumours using the Mann-Whitney non-parametric test in GraphPad Prism 
6. A p value of ≤ 0.05 indicated statistical significance.  
 
In addition, the average 2-∆∆Ct values calculated for miRNA-21 and miRNA-34a will be used as 
cut off values to classify MSI and MSS tumours into cases with high or low miRNA expression 
levels (Appendices G to J).  
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Chapter Three 
3. Results 
3.1. The clinicopathologic/demographic features of all the CRC cases 
The majority (78%) of our cases were older than 50 years and only 22% were younger than 50 
years. There were more females (57/100) than males (43/100). Furthermore, thirty three (33%) 
cases presented with stage I, 14% with stage II, 44% with stage III and only 9% presented with 
stage IV of the tumour. Concerning grade of the tumour, 22% were well differentiated (Grade 
1), 68% moderately differentiated (Grade 2) and 10% were poorly differentiated (Grade 3). 
Only two of the poorly differentiated cases were of the signet ring subtype. Sixty four (64%) 
cases did not present with lymph node metastasis whilst 36% cases showed lymph node 
metastasis. Forty four (44%) had a tumour in the right colon and 56 (56%) in the left colon 
(Table 3.1).   
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Table 3. 1: Clinicopathologic/demographic data of the 100 CRC cases. 
 
Age  ≤ 50 = 22 
> 50 = 78 
Sex Ratio (Male: Female) 43:57 
Stage  
I 33 
II 14 
III 44 
IV 9 
Grade  
1 22 
2 68 
3 10 
Lymph node metastasis   
No 64 
Yes 36 
Site of tumour  
Right 44 
Left 56 
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3.2. Immunohistochemistry 
3.2.1. E-cadherin, N-cadherin, vimentin, snail-1 and CD44v6 expression levels in CRC. 
There was heterogeneity of staining in different parts of the tumour. However, the percentage 
staining was calculated on the whole quantity of tumour present for evaluation, which therefore 
took the heterogeneity into account. In addition, we specifically looked at the interface between 
the tumour and adjacent normal colon for an internal control for the antibodies where it was 
relevant.  
 
 
IHC stains for E-cadherin, N-cadherin, vimentin, snail-1 and CD44v6 proteins were used to 
ascertain EMT in our cohort. Of the 100 cases, only 23% (Table 3.2) showed membrane 
expression of the E-cadherin protein (Figure 3.1). In addition, 77% tumours showed down-
regulated E-cadherin expression. E-cadherin was down-regulated in the cases with the signet 
ring morphology as well as those with no signet rings. N-cadherin and vimentin were expressed 
in only 2% of our cases (Table 3.2). N-cadherin was expressed in the membrane in both cases 
(Figure 3.2C and Figure 3.2D). Among the 2 cases that expressed vimentin, 1 showed 
membrane expression (Figure 3.3C) and the other one showed cytoplasmic expression. Snail-
1 showed nuclear expression (Figure 3.4C) in 35% (35/100) of the cases. Lastly, membrane 
expression of CD44v6 (Figure 3.5C) was seen in only 22% (4/100) of the cases. These IHC 
data therefore show that EMT is not seen in CRCs of our cohort (Table 3.2). 
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Table 3. 2: Expression of EMT and stem cell markers in 100 CRC cases 
EMT marker Positive expression  Negative expression 
E-cadherin 23%  77% 
N-cadherin 2%  98% 
Vimentin 2%  98% 
Snail-1 35%  65% 
CD44v6 (stem cell) 22%  78% 
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(A) E-cadherin negative control 
 
 
(B) E-cadherin positive control 
 
 
(C) E-cadherin membrane expression 
 
 
(D) E-cadherin cytoplasmic expression 
Figure 3. 1: The negative (A) and positive controls (B) are shown. IHC stains showing E-
cadherin in the membrane (C) and cytoplasm (D) at 40x magnification. 
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(A) N-cadherin negative control 
 
 
(B) N-cadherin positive control 
 
 
(C) N-cadherin membrane 
 
 
(D) N-cadherin membrane 
Figure 3. 2: Negative (A) and positive (B) controls are shown. IHC stains showing N-
cadherin membrane expression (C) and (D) at 40x magnification. 
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(A) Vimentin negative control 
 
 
(B) Vimentin positive control 
 
 
(C) Vimentin membrane expression 
 
 
(D) Vimentin negative expression 
Figure 3. 3: Negative (A) and positive (B) controls are shown. IHC stains showing membrane 
expression (C) of vimentin. A negative expression with background staining is shown (D). 
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(A) Snail-1 negative control 
 
 
(B) Snail-1 positive control 
 
 
(C) Snail-1 nuclear staining 
 
 
(D) Snail-1 cytoplasmic staining 
Figure 3. 4: Negative (A) and positive (B) controls are shown. IHC stains showing snail-1 
nuclear (C) and cytoplasm (D) expression at 40 x magnification. 
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(A) CD44v6 negative control 
 
 
(B) CD44v6 positive control 
 
 
(C) CD44v6 membrane expression 
 
 
(D) CD44v6 cytoplasmic expression 
Figure 3. 5: Negative (A) and positive (B) controls are shown. IHC stains showing CD44v6 
membrane (C) and cytoplasm (D) expression at 40 x magnification. 
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3.3. Correlations between EMT proteins and clinicopathologic features 
 
 
The protein expression levels were stratified into high or low expression groups according to 
the scores obtained. The E-cadherin immunoreactivity categorised into negative and positive 
expression was not associated with any of the clinicopathologic features of the tumour (Table 
3.3). Furthermore, there was no statistical significance in E-cadherin expression between stage 
3 and stage 4 compared to other stages (Appendix O). There were also no significant 
correlations between other EMT markers (N-cadherin, vimentin, snail1 and CD44v6) and 
clinicopathologic data (Appendix L, I-V). Moreover, there was no relationship between E-
cadherin and mesenchymal/stem cell (N-cadherin, vimentin, snail-1 and CD44v6) markers, 
(Appendix M, I-IV). 
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Table 3. 3: Relationship between E-cadherin and clinicopathologic/demographic features in 
100 CRC cases. 
Clinicopathologic 
features 
E-cadherin positive 
expression 
E-cadherin negative 
expression 
P 
value 
    
Age     0.5 
≤ 50  4/22(91%) 18/22(9%)   
> 50 19/78(81%) 59/78(19%)   
        
Gender     0.6 
Male 9/43(93%) 34/43(7%)   
Female 14/57(75%) 43/57(25%)   
        
Stage      0.2 
I 9/33(85%) 24/33(15%)   
II 3/14(93%) 11/14(7%)   
III 7/44(77%) 37/44(23%)   
IV 4/9(89%) 5/9(11%)   
        
Grade     0.1 
1 5/22(82%) 17/22(18%)  
2 18/68(88%) 50/68(12%)                                                                          
3 0/10(0%) 10/10(100%)   
        
Lymph nodes     0.8 
Yes 8/36(78%) 28/36(22%)   
No 15/64(86%) 49/64(14%)   
        
Site of tumour     0.3 
Right 8/44(80%) 36/44(20%)   
Left 15/56(86%) 41/56(14%)   
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3.4. Clinicopathologic/demographic features of the 59 CRC cases used for miRNA 
qRT-PCR 
 
Seventeen (29%) patients were younger or equal to the age of 50 years and 42 (71%) were 
older than 50 years. The cases consisted of 26 males (44%) and 33 females (56%). Fifteen 
cases (25%) were stage I, 7 (12%) stage II, 29 (49%) stage III and 8 (14%) stage IV. Eleven 
cases (19%) were well differentiated (Grade 1), 68% (40/59) moderately differentiated (Grade 
2) and only 8 (14%) were poorly differentiated. Thirty four (58%) patients did not present with 
lymph node metastases, while 25 (42%) had at least one node affected. Thirty cases (51%) had 
a tumour in the right colon and 29 (49%) in the left colon (Table 3.4). 
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Table 3. 4: Clinicopathologic/demographic data of the 59 CRC cases used for miRNA qRT-
PCR 
Age  ≤ 50 = 17 
> 50 = 42 
Sex Ratio (Male: Female) 26:33 
Stage  
I 15 
II 7 
III 29 
IV 8 
Grade  
1 11 
2 40 
3 8 
Lymph node metastasis   
No 34 
Yes 25 
Site of tumour  
Right 30 
Left 29 
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Table 3. 5: Expression of EMT and stem cell markers in the 59 CRC cases used for miRNA 
qRT-PCR 
EMT marker Positive expression  Negative expression 
E-cadherin 11/59  48/59 
N-cadherin 2/59 57/59 
Vimentin 1/59 58/59 
Snail-1 7/59  52/59 
CD44v6 (stem cell) 12/59 47/59 
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3.5. miRNA-21 expression levels in CRC 
 
There is a statistically significant increase in miRNA-21 expression levels in the tumour 
relative to the normal tissues. The average 2-∆∆Ct values of miRNA-21 expression for the tumour 
and normal tissues were 3.5 and 2.6, respectively (Appendices E and G).  
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Figure 3. 6: miRNA-21 expression levels in the tumour (miRNA-21 T) relative to the normal 
tissues (miRNA-21 N). 
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3.5.1. miRNA-21 expression levels in clinicopathologic features 
 
 
There were statistically significant differences between miRNA-21 expression levels and 2 
clinicopathologic features (Figure 3.7B and Figure 3.7C) of the tumour. There was no 
relationship between miRNA-21 expression levels and other features (Figure 3.7A and Figure 
3.7D). In addition, there were high miRNA-21 expression levels in patients older than 50 years 
compared to those younger or equal to 50 years of age, p=0.04 (Figure 3.8). 
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(A): miRNA-21 vs stage 
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(B): miRNA-21 vs grade 
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(C): miRNA-21 vs lymph node metastasis 
status 
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(D): miRNA-21 vs tumour site 
 
Figure 3. 7: miRNA-21 expression levels in clinicopathologic features. (A): Stage, (B): 
Grade, (C): lymph node (LN) metastasis and (D): Site of tumour (Left and Right). 
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Figure 3. 8: miRNA-21 expression levels in patients equal to or younger than 50 years (</= 
50 years) vs those older than 50 years (> 50 years) of age. 
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3.5.2. miRNA-21 expression levels and EMT in CRC 
 
 
There were no significant correlations between miRNA-21 and E-cadherin expression levels 
(Figure 3.9A). There were significantly higher miRNA-21 expression levels in snail-1 negative 
cases, p=0.03 (Figure 3.9B) and N-cadherin negative cases, p=0.04 (Figure 3.9C). We could 
not obtain a statistical significant value for miRNA-21 and vimentin (Figure 3.9D), since there 
was only one individual that expressed this protein among the 59 cases (Table 3.5). There was 
also no significant difference between miRNA-21 and CD44v6 expression levels (Figure 3.10).    
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(A) miRNA-21 vs E-cadherin 
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(B) miRNA-21 vs Snail-1 
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(C) miRNA-21 vs N-cadherin 
V
im
e
n
ti
n
 +
V
im
e
n
ti
n
 -
0
5
1 0
1 5
m
iR
N
A
-2
1
 e
x
p
r
e
s
s
io
n
 l
e
v
e
l
 
 
(D) miRNA-21 vs Vimentin 
 
Figure 3. 9: (A): The differences in miRNA-21 expression levels among cases with a positive 
(E-cad +) and negative (E-cad -) E-cadherin protein expression; (B): miRNA-21 expression 
levels in snail1 positive (Snail1 +) and snail1 negative (Snail1 -) cases; (C): miRNA-21 
expression levels in N-cadherin positive (N-cad +) and N-cadherin negative (N-cad -) cases 
and (D): miRNA-21 expression levels in vimentin positive (vimentin +) and vimentin 
negative (vimentin -) cases 
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Figure 3. 10: The differences in miRNA-21 expression levels among cases with a positive 
CD44v6 (CD44v6 +) and negative CD44v6 (CD44v6 -) protein expression. 
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3.6. miRNA-34a expression levels in CRC 
 
The results show significantly up-regulated miRNA-34a expression levels in the cancerous 
compared to cancerous tissues. The average 2-∆∆Ct values for miRNA-34a expression for 
tumour and normal tissues were 0.6 and 0.22, respectively (Appendices E and I).    
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Figure 3. 11: miRNA-34a expression levels in the tumour (miRNA-34a T) relative to normal 
tissues (miRNA-34a N). 
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3.6.1. miRNA-34a expression levels in clinicopathologic features 
 
There were no associations between miRNA-34a expression levels and clinicopathologic 
features of the tumour (Figure 3.12). In addition, there was no statistical significance between 
miRNA-34a expression levels and age (Figure 3.13). 
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(A): miRNA-34a vs stage 
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(B): miRNA-34a vs grade 
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(C): miRNA-34a vs lymph node 
metastasis status 
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(D): miRNA-34a vs tumour site 
 
Figure 3. 12: miRNA-34a expression levels in clinicopathologic features. (A): Stage, (B): 
Grade, (C): lymph node (LN) involvement and (D): Site (Left and Right colon) of tumour. 
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Figure 3. 13: miRNA-34a expression levels in patients younger than or equal to 50 years (</= 
50 years) vs those older than 50 years (> 50 years) of age. 
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3.6.2. miRNA-34a expression levels and EMT in CRC 
 
 
There was no statistical significance between miRNA-34a expression levels and E-cadherin 
protein expression, p=0.1 (Figure 3.14A). Furthermore, no correlation was observed between 
miRNA-34a and N-cadherin expression levels (Figure 3.14C). Moreover, we could not get a 
statistical significant value for miRNA-34a and vimentin (Figure 3.14D). MiRNA-34a 
expression was associated with snail-1 expression, p=0.03 (Figure 3.14B). There was also a 
correlation between miRNA-34a and CD44v6 expression levels, p=0.05 (Figure 3.15).  
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(A): miRNA-34a vs E-cadherin  
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(B): miRNA-34a vs Snail-1 
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(C): miRNA-34a vs N-cadherin  
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(D): miRNA-34a vs Vimentin 
Figure 3. 14: The differences in miRNA-34a expression levels between cases with E-cadherin 
negative (E-cad -) and positive (E-cad +) protein expression; (B): miRNA-34a expression 
levels in snail-1 negative (Snail-1) and snail-1 positive (Snail-1 +) cases; miRNA-21 
expression levels in N-cadherin positive (N-cad +) and N-cadherin negative (N-cad -) cases 
and (D): miRNA-21 expression levels in vimentin positive (Vimentin +) and vimentin 
negative (Vimentin -) cases. 
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Figure 3. 15: The differences in miRNA-34a expression levels among cases with a positive 
CD44v6 (CD44v6 +) and negative CD44v6 (CD44v6 -) protein expression. 
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3.7. Significance of miRNA-21 and miRNA-34a in MSI 
 
3.7.1. MSI and MSS tumours in 59 cases 
 
 
Microsatellite unstable (MSI) tumours were defined as those which had a loss of expression of 
one or two mismatch repair proteins while microsatellite stable (MSS) cases expressed all the 
MMR proteins. Of the 51 CRC cases not previously tested for HNPCC, 5 showed loss of MLH1 
expression, 5 showed loss of MSH2 expression and 6 showed loss of MSH6 expression. In 
addition, 7 of the 8 known HNPCC cases showed loss of MLH1 expression, 3 showed loss of 
MSH2 expression and 5 showed loss of MSH6 expression. Of these 59 cases, there were a total 
of 20 cancers with MSI (Appendix F, blue highlight).  
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3.7.1.1. miRNA-21 expression levels in MSI vs MSS tumours 
 
 
There were higher miRNA-21 expression levels in MSS vs MSI tumours, p=0.02 (Figure 3.16). 
In addition, 22 of 39 MSS tumours showed high miRNA-21 expression (Appendix H). High 
miRNA-21 expression levels were observed in only 9 of the 20 MSI cases (Appendix G).  
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Figure 3. 16: miRNA-21 expression levels in microsatellite unstable (MSI) and microsatellite 
stable (MSS) tumours. 
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3.7.1.2. miRNA-34a expression levels in MSI vs MSS tumours 
 
There was no significant difference in miRNA-34a expression between MSI and MSS tumours, 
p=0.2 (Figure 3.17). High miRNA-34a expression levels were seen in 14 of 20 MSI cases 
(Appendix I). Moreover, there were high miRNA-34a expression levels in 16 of the 39 MSS 
tumours (Appendix J).     
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Figure 3. 17: The miRNA-34a expression levels in microsatellite unstable (MSI) and 
microsatellite stable (MSS) tumours. 
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Chapter Four 
4. Discussion 
4.1. Clinicopathologic and demographic features of our cohort 
 
 
This study investigated the role of miRNAs and EMT in the development and progression of 
CRC. The cases were analysed for clinicopathologic/demographic features which included 
gender, age, stage, grade, tumour site and lymph node metastasis (Appendix A). Our results 
show higher incidence rates of CRC in females (57%) than males (43%) which is similar to 
published data (Globocan, 2012; Ali et al., 2014). Furthermore, CRC is frequently seen in 
individuals over the age of 50 (78% cases). The majority of our patients presented with stage 
III disease (Table 3.1) indicating advanced disease, although there were only a few individuals 
with stage IV tumours.  
 
With regard to grade of the tumour, 22% were similar in appearance (well differentiated) to 
normal colonic glands, suggesting that the tumour cells were less aggressive. In addition, only 
10% of the cases had poorly differentiated tumours. The majority (68%) of the cases had 
moderately differentiated tumours (Table 3.1). In addition, although one previous study 
reported lymph node metastasis in 67% of CRC cases (Chua et al., 2009), the present 
investigation shows 36% of patients having lymph node metastasis. 
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4.2. EMT in CRC 
 
CRC is characterized by infiltrative growth which is associated with epithelial-mesenchymal 
transition (EMT). EMT is frequently seen at the invasive front of CRCs and is accompanied 
by an increased expression of mesenchymal markers e.g., N-cadherin and vimentin (Craene 
and Berx, 2013). Prerequisites for EMT are changes in the epithelial phenotype of tumour cells, 
i.e., the loss of epithelial polarity and gain of motility (Garg, 2013). Loss of epithelial 
phenotype is mediated by down-regulation of E-cadherin, a cell adhesion molecule localized 
at the cell membrane of epithelial cells.  
 
In order to determine the presence or absence of the EMT phenotype, immunohistochemical 
analysis of 4 EMT markers was carried out and the expression levels were correlated with the 
clinicopathologic/demographic features. The down-regulated E-cadherin expression in 77% of 
cases (Table 3.2) indicates loss of the epithelial phenotype. However, only 26% (Appendix C) 
showed a mesenchymal feature, indicated by a positive expression of snail-1 (23 cases, green 
highlight); N-cadherin (1 case; yellow highlight) or vimentin (2 cases; blue highlight). It was 
noted that 10 of the cases which showed positive expression of E-cadherin also had up-
regulated snail-1 expression (Appendix C; red highlight). This suggests that the transcription 
factor snail-1 did not repress E-cadherin in those cases.  
 
It has been reported that snail-1’s effectual and complete repression of E-cadherin as well as 
EMT-activating ability entails having integral ZF1 and ZF2 structures. However, alterations in 
the ZFs may lead to a decreased repressor activity of snail-1 (Villarejo et al., 2014). It is 
therefore probable that the inability of snail-1 to repress E-cadherin in the 10 cases is linked to 
its decreased repressor function due to molecular changes (e.g., mutations) that may have 
occurred. In addition, snail-1 not only represses E-cadherin but also activates the expression of 
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mesenchymal factors, i.e., N-cadherin and vimentin (Bezdekova et al., 2012; Zhang et al., 
2013). However, all the cases that showed down-regulated E-cadherin expression and gain of 
snail-1 expression (green highlight) did not express N-cadherin and vimentin (orange 
highlight). We therefore suggest that snail-1 may have failed to activate N-cadherin and 
vimentin expression (mesenchymal phenotype).  
 
Although the 23 cases possess an EMT feature (i.e., loss of E-cadherin and gain of snail-1), 
they cannot be deemed to have undergone a complete epithelial to mesenchymal transition, 
since they did not show expression of the mesenchymal phenotype (Appendix C; orange 
highlights). Furthermore, we suggest that 3 of the 100 cases have undergone EMT since they 
show both a loss of epithelial and gain of mesenchymal phenotype (Appendix C, blue and 
yellow highlights). However, it must be noted that these cases did not express snail-1. 
Therefore, our results infer that the down-regulated E-cadherin expression in those 3 cases may 
be explained by molecular modifications in CDH1. In addition, since the repression of E-
cadherin also involves the participation of other EMT-ATFs (e.g., snail-2, twist and zeb) in 
cancer, it is possible that some of these markers may have played a role in repressing E-
cadherin. Therefore, further research would have to explore and determine the expression of 
other EMT-TFs.  
 
Our results did not show a relationship between E-cadherin expression levels and mesenchymal 
transcription factors i.e., N-cadherin, vimentin, and snail-1 (Appendix M) in this cohort. A 
previous study by Kroepil et al (2013) also did not observe any significant association between 
E-cadherin and snail-1 expression levels. However, other investigations (Fan et al., 2013; 
Findlay et al., 2013; Toiyama et al., 2013) showed an association between increased snail/twist 
and decreased E-cadherin membranous expression. This infers that these two markers induced 
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EMT and therefore facilitate the progression of the disease. These studies also observed high 
expression levels of snail/twist in more than 70% of their cases, which is different from our 
findings that showed 35% snail-1 expression.  
 
Furthermore, there was no association between expression levels of all the EMT markers (E-
cadherin, N-cadherin, snail and vimentin) and clinicopathologic features (lymph node 
metastasis, grade, stage and tumour site) in our study (Appendix L I-V). E-cadherin expression 
did not correlate with lymph node metastasis, grade and stage. This implies that E-cadherin is 
not involved in the metastatic process.  
 
The differences between our findings and other studies regarding the expression profile of the 
EMT markers could be due to a number of factors. These include the different clones of 
antibodies used, sample type/sample size included and scoring systems. Our scoring methods 
(adopted from Rubin et al., 2001; Nakajima et al., 2004; Franci et al., 2009; Fan et al., 2013; 
Saito et al., 2013) were different from the ones used by Toiyama et al (2013) and Kroepil et al 
(2013).  In the study by Toiyama et al (2013), vimentin expression was determined by two 
pathologists using an immune-reactivity scoring system through multiplying intensity and 
proportion scores, while E-cadherin expression was determined using qRT-PCR. Findlay et al 
(2013) also used qRT-PCR to determine E-cadherin, vimentin, snail and slug expression levels. 
Furthermore, Kroepil et al (2013) used Blechschmidt’s semi-quantitative method to determine 
E-cadherin and snail expression (Blechschmidt et al., 2008). This is the first study to investigate 
the role of EMT in our population. Therefore, further research in this area will contribute to the 
body of knowledge. 
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4.2.1. EMT and CD44v6 in CRC 
 
EMT is also related to the cancer stem cell phenotype and the presence of these cancer stem 
cells is associated with metastasis (Fan et al., 2012; Du et al., 2013; Mashita et al., 2014; Saito 
et al., 2013). Our study showed low expression of CD44v6 in 78% of the cases (Table 3.2). 
This is an indication that cancer stem phenotype was not seen in this cohort. Whilst there were 
no significant correlations between CD44v6 and EMT markers (Appendix N), our results 
showed an inverse relationship between CD44v6 and E-cadherin expression in 35 cases 
(Appendix B, purple and black/white highlights). Twenty one of these cases expressed CD44v6 
while E-cadherin was down-regulated (Appendix B, black/white highlight). The remaining 
cases (i.e., 14 cases) showed E-cadherin expression while CD44v6 was not expressed 
(Appendix B, purple).  
 
These findings concur with previous studies which also showed a similar correlation (Saito et 
al., 2013; Mashita et al., 2014). We also observed a concurrent expression of CD44v6 and E-
cadherin in 8 cases (Appendix B, pink highlight). Furthermore, 3 of the 8 cases also showed 
snail-1 expression. Previous investigations reported that the stem cell and EMT phenotypes 
play a role in the advancement of this cancer, however, in our study these phenotypes are absent 
in more than 75% cases. Therefore, since EMT involves a loss of epithelial phenotype with a 
gain of mesenchymal and stem cell phenotypes, our results indicate that EMT is not prevalent 
in CRCs seen in our population.  
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4.3. MiRNA expression levels in colorectal cancer 
 
 
MiRNA dysregulation is a common feature of human cancers as they control the expression of 
oncogenes and tumour suppressors, thereby functioning as onco-miRNAs or tumour 
suppressor miRNAs (Shenouda and Alahari, 2009). Thus far, the studies related to the role of 
miRNAs in CRC have been sparse. (Ping et al., 2014).  
 
 
4.3.1. miRNA-21 in CRC  
 
Various studies concluded that miRNA-21 acts an oncogene in CRC (Toiyama et al., 2012; 
Ferraro et al., 2013; Xiong et al., 2013; Yang et al., 2015). These conclusions were based on 
the fact that miRNA-21 was up-regulated in the cancer tissue when compared to their 
corresponding normal tissues. Our investigation showed similar results (Figure 3.6), supporting 
the suggestion regarding the oncogenic role of miRNA-21 in this disease. Furthermore, high 
miRNA-21 expression levels have been recently shown to be associated with poorly 
differentiated tumours, larger tumours, advanced stage (III, IV), poor survival, distant and 
lymph node metastatic CRCs, implying that this miRNA is involved in promoting metastasis 
and progression of the cancer (Toiyama et al., 2012; Xiong et al., 2013). Similarly, there was 
an association between high miRNA-21 expression and increasing grade (Figure 3.7B). 
Additionally, although there was no statistical significance, the increased miRNA-21 
expression levels in stage III tumours (Figure 3.7A) may also be indicative of miRNA-21’s 
potential role in the advancement of the disease (Slabby et al., 2007; Schetter et al., 2008).  
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There was also no statistical correlation when miRNA-21 expression was compared with 
tumour site (Figure 3.7D). There were high miRNA-21 expression levels in the cases that did 
not show lymph node metastasis (Figure 3.7C, p =0.01), suggesting that miRNA-21 is 
associated with low stage tumours. Furthermore, our study shows significantly increased 
miRNA-21 expression in older patients (Figure 3.8). Other studies thus far have failed to show 
this association.  
 
4.3.2. miRNA-21 and EMT in CRC 
 
 
Although research on the role of miRNA-21 in EMT is increasing in other cancers, there are 
only a few studies on colorectal cancer. Thus far, only two studies have investigated the role 
of miRNA-21 and EMT in CRC (Ferraro et al., 2013; Yue et al., 2015). Our results show an 
inverse association between miRNA-21 and snail-1 expression levels (Figure 3.9B, p=0.03). 
This infers that miRNA-21 did not activate snail-1 expression in this cohort. This study also 
shows that miRNA-21 does not stimulate N-cadherin (Figure 9C) and vimentin (Figure 3.9D) 
expression. It is uncommon for miRNA-21 to show increased expression in the tumours with 
a down-regulated snail-1 expression (i.e., absence of an EMT feature).  Therefore, this shows 
that miRNA-21 does not play a role in the induction of EMT. 
 
The results obtained from the present study are different to those published by Ferraro et al., 
(2013) and Yue et al., (2015). These two studies showed an association between high miRNA-
21 expression and increased expression of snail-1 and N-cadherin. These findings imply that 
miRNA-21 plays a role in the activation of EMT and hence the progression of the cancer. 
Although miRNA-21 serves as an oncomir and has been found to activate EMT in different 
cancers, including CRC (Bornachea et al., 2012; Han et al., 2012; Chan and Wang, 2015; Sun 
et al., 2015), our findings infer that miRNA-21 does not seem to stimulate EMT nor contribute 
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to the progression of CRC in this cohort. The findings from the current study may be indicative 
that some of the EMT transcription factors (e.g., snail-1) are not regulated by miRNA-21.   
 
Furthermore, our study did not show a statistical significance between miRNA-21 and E-
cadherin expression (Figure 3.9A). We therefore suggest that miRNA-21 did not regulate E-
cadherin expression in this cohort. These results are different from the two investigations 
(Ferraro et al., 2013; Yue et al., 2015) which reported elevated miRNA-21 expression levels in 
cell lines with down-regulated E-cadherin expression. 
 
The inability of miRNA-21 to induce the EMT phenotype could be explained in various ways: 
e.g., there are transcription factors (e.g., AP-1, ETS1 and LIF) that bind and up-regulate 
miRNA-21 expression, causing it to stimulate EMT. Therefore, it is likely that these factors 
failed to stimulate miRNA-21 function. In addition, there are tumour suppressor genes (e.g., 
PTEN, PDCD4, SPRY2, RECK, TIAM1, TIPM3 and ITGβ4) that target and block the function 
of miRNA-21 (Liu et al., 2011; Xiong et al., 2013; Yang et al., 2015). Therefore, it is also 
possible that these genes may have played a role in inhibiting miRNA-21 effects.  
 
Ferraro and Yue showed that AP-1, ETS1 and LIF increased miRNA-21 expression levels. 
Increased PTEN protein expression in their study was associated with decreased miRNA-21 
expression. Therefore, it was inferred that PTEN plays a role in blocking the effects of miRNA-
21 in EMT. There may also be genetic variations within our population cohort which could 
possibly explain the differences in the miRNA expression levels.  
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In addition, CRC samples obtained from South Africa compared to the ones from Greece 
(Ferraro et al., 2013) and USA (Yue et al., 2015) may also have genetic differences. In the light 
of these results, the regulatory role of miRNA-21 in EMT is still unclear in CRC since there 
have only been three studies (including the current study) conducted so far. This is the first 
study to investigate the role of miRNA-21 and EMT in a South African landscape. Therefore, 
further research needs to be carried out in order to provide a clear understanding about the 
actual role of miRNA-21 and EMT in this disease.  
 
 
Researchers who have investigated the role of miRNA-21 and EMT in other human cancers 
(breast, renal and prostate cancers) also obtained different results from my study (Han et al., 
2012; Coppola et al., 2013; Cao et al., 2016; Yan et al., 2016). These investigations (from China 
and Italy) analysed the expression of 4 EMT markers (E-cadherin, N-cadherin, vimentin and 
slug) in cell lines induced with miRNA-21. In concordance with Ferraro and Yue, they also 
showed an association between the mesenchymal phenotype (i.e. increased N-cadherin, 
vimentin and snail-2 expression) and increased miRNA-21 expression. Furthermore, they 
indicated that high miRNA-21 expression was correlated with down-regulated E-cadherin 
expression. These findings implied that miRNA-21 activates EMT. Among these previous 
studies, Cao et al (2016) observed significantly increased miRNA-21 expression in cases with 
normal E-cadherin expression.  
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4.4. miRNA-34a in colorectal cancer 
 
MiRNA-34a is said to act as a tumour suppressor based on its down-regulated expression in 
cancer, including CRC (Nugent et al., 2012; Ma et al., 2014; Aherne et al., 2014). However, 
our findings indicate that miRNA-34a is up-regulated in our patient cohort (Figure 3.11). Our 
results are similar to the findings by Aherne et al (2014). The data obtained by Nugent and Ma 
are different from our results. Therefore, the actual role of miRNA-34a in this cancer requires 
further investigation.  
 
It is known that a single miRNA can either act as an oncogene or tumour suppressor depending 
on the type of tissue (Berindan-Neagoe et al., 2014). Therefore, it is possible that miRNA-34a 
may also have other functions in this cancer. We did not observe an association between 
miRNA-34a expression and clinicopathologic features (Figure 3.12). MiRNA-34a expression 
was not associated with stage, grade or lymph node metastasis (Figure 3.12A, B and C), 
implying that it does not play a role in the development and metastatic process of the tumour. 
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4.4.1. miRNA-34a and EMT in CRC 
 
 
Although research on the role of miRNA-34a and EMT in the development of other cancers is 
increasing, research related to miRNA-34a in colorectal cancer is sparse. Thus far, only two 
investigations have determined the relationship between miRNA-34a and EMT in this disease 
(Du et al., 2012; Rokavec et al., 2014). The findings from our study showed a significant 
relationship between increased miRNA-34a and low snail-1 expression (Figure 3.14B, p=0.03). 
Similar to the two previous studies (Du et al 2012, Rokavec et al 2014), our findings imply that 
miRNA-34a may be repressing snail-1 expression, thereby inhibiting EMT in CRC. Likewise, 
miRNA-34a has been shown to inhibit EMT by decreasing the expression of EMT-TFs in other 
cancers (Sun et al., 2015; Li et al., 2016). In light of these findings, miRNA-34a may be 
functioning as a tumour suppressor which inhibits snail-1 expression.  
 
We cannot make the same inference about miRNA-34a and N-cadherin (Figure 3.14C), since 
there was no statistical significance when these were compared. Furthermore, our study did not 
observe an association between miRNA-34a and E-cadherin expression (Figure 3.14A). 
Although there was no significant relationship, miRNA-34a was increased in the cases that 
showed E-cadherin expression. These data infer that miRNA-34a plays a role in regulating the 
EMT process.  
 
Furthermore, Du et al (2012) also reported that miRNA-34a inhibited EMT by targeting and 
decreasing proteins of the notch pathway, i.e., notch1 and jagged1 proteins. Similarly, a study 
by Qiao et al., (2015) also indicated that miRNA-34a reversed EMT through suppressing the 
expression of TGF-β and Smad4. This resulted in increased E-cadherin expression levels while 
snail and N-cadherin expression were decreased (Qiao et al., 2015). Based on these 
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investigations, miRNA-34a also regulates EMT through targeting other biological pathways in 
CRC.  
 
 
4.4.2. MiRNA-21 and miRNA-34a vs CD44v6 in CRC 
 
 
MiRNAs have been implicated in the regulation of cancer stem cell related proteins. Therefore, 
a better perspective of the relationship between miRNAs and stem cells could aid in 
understanding the development and progression of CRC. MiRNA-34a was significantly 
increased (p=0.05) in the cases that showed low CD44v6 expression (Figure 3.15), suggesting 
that miRNA-34a may be regulating the cancer stem cell phenotype. In addition, since there is 
an association between stem cell and EMT phenotypes, this further infers that miRNA-34a 
prevents EMT in our study cohort. Similar findings were also reported in pancreatic, prostate, 
glioblastoma and breast cancers (Liu et al., 2011; Nalls et al., 2011). MiRNA-34a was also 
shown to repress stem cell features in colon, breast and glioblastoma cancers through targeting 
notch1 (Li et al., 2009; Bu et al., 2013; Kang et al., 2015). These findings then suggest that 
miRNA-34a may have a role in inhibiting metastasis and progression of these cancers. These 
data also provide further indication that CD44v6 is a target of miRNA-34a, however, we did 
not find any association between miRNA-21 and CD44v6 (Figure 3.10). 
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4.5. Significance of miRNA-21 and miRNA-34a in MSI  
 
 
To date, there has been very little research conducted on the impact of miRNAs related to 
microsatellite instability (MSI). Furthermore, MSI tumours have different clinical and 
pathologic features from MSS tumours. Generally, patients with MSI have better survival and 
are less likely to have metastases than MSS tumours (Saridaki et al., 2014). It is therefore stated 
that MSI-associated miRNAs also have a prognostic significance (Dong et al., 2014). The 
current study observed a correlation between increased miRNA-21 expression levels and MSS 
tumours (Figure 3.16, p=0.02). In addition, we noticed high miRNA-21 expression in a greater 
proportion of MSS (56.4%; Appendix H) than MSI tumours (45%; Appendix G). These results 
thus suggest that further studies investigate miRNA-21 as an indicator of prognosis.  
 
 
Furthermore, with regard to miRNA-34a, we did not see an association between its expression 
levels and MSI status (Figure 3.17, p=0.2). However, a greater percentage of MSI tumours 
(70%; Appendix I) had increased miRNA-34a expression than MSS tumours (41%; Appendix 
J).  
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4.6. Strengths and limitations of IHC in the study 
 
This investigation determined the expression of four EMT markers using IHC. All of the cases 
which were used came from the same laboratory. This implies that these cases had been 
subjected to similar pre-analytical conditions such as formalin fixation, processing paraffin 
embedding and storage. Although some cases had been in the archives longer than others, they 
were interpreted by a single pathologist over a relatively short space of time. The various 
factors to consider when performing IHC include antibody selection (i.e., specific clone of the 
antibody), method of antigen retrieval, thickness of sectioning and blocking methods, i.e., 
blocking endogenous peroxidise activity (Sompuram et al., 2004). In the present study, two 
antibodies (vimentin and snail-1) had background and non-specific staining. Vimentin had a 
background staining of the stroma which was not considered as a positive result. Snail-1, on 
the other hand, stained the majority of the cases in the cytoplasm where we only considered 
nuclei staining as a positive result. Furthermore, the antibodies may have not reached the whole 
tissue sections while it was applied manually, as compared to an automatic method. 
 
In addition, since formalin-fixed tissues require an antigen retrieval step before IHC staining, 
antigen retrieval buffers were used to unmask the antigen sites, allowing the antibodies to bind 
(Fowler et al., 2011). The retrieval buffers can sometimes damage the morphology of the 
section, which in turn affects staining, however, this did not prove to be problematic in this 
study. With regards to sectioning, a delay between sectioning and IHC may lead to false-
negative results (Economou et al., 2014). This investigation sectioned all tissue blocks prior to 
performing IHC. This may have led to differences in staining as some of the stains failed to 
work. Moreover, the blocking step, using an appropriate buffer, was performed prior to 
incubating the sample with the primary antibody. Therefore, sufficient washing of the blocking 
buffer is critical to remove excess protein that may prevent detection of the target antigen 
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(Buchwalow et al., 2011). Some of these factors may have possibly played a role in the 
problems encountered including insufficient, non-specific and high background staining.  
 
Although the above mentioned challenges were encountered, all the tissue blocks were cut with 
the same microtome ensuring equal thickness of sections. Whole tissue sections which served 
to overcome the problem of heterogeneity staining were used for each case rather than small 
tissue microarrays. The methods were optimized for each antibody prior to commencing with 
staining of the test sections. During optimization, we worked out the best incubation period 
and concentration for each primary antibody. Appropriate positive and negative controls were 
used for the antibodies where internal controls were present. Additionally, previously described 
scoring systems were used to evaluate the IHC staining where the intracellular location of 
staining and the type of cell were carefully considered. Staining was repeated if these did not 
stain properly and sections were coded to avoid bias when interpreting IHC results.    
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Only a few studies have been conducted on the role of miRNAs and EMT in colorectal cancer. 
In addition, this is the first investigation to determine the role of miRNAs and EMT in the 
Western Cape. Therefore, further research is required to better understand the role of miRNA-
21, miRNA-34a and EMT in colorectal cancer.  
 Our study showed that the majority of the cases were negative for EMT, implying that 
EMT is not involved in the development and progression of CRC in this cohort.  
 Further, high miRNA-21 expression was associated with low expression of N-cadherin 
and snail-1. Therefore, miRNA-21 does not appear to activate EMT, suggesting that 
there could be other factors that may contribute to loss of its EMT inducing activity.  
 There was an association between increased miRNA-21 expression levels and grade 2 
tumours, absence of lymph node metastasis and older patients.   
 We also observed that increased miRNA-34a expression was significantly associated 
with low expression of snail-1. This infers that miRNA-34a plays a role in reversing 
EMT. 
 There was no association between miRNA-34a expression and 
clinicopathologic/demographic features.  
 This study also indicated an association between increased miRNA-21 expression and 
MSS tumours, while no correlation was observed between miRNA-34a and 
microsatellite status.  
In conclusion, our investigation indicates that there is an inverse relationship between miRNA 
(miRNA-21 and miRNA-34a) expression and two EMT (N-cadherin and snail-1) markers in 
our colorectal cancer cohort. Our data also show that both miRNA-21 and miRNA-34a do not 
seem to play a role in the progression of the cancer.  
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Future studies and recommendations.   
 
Although our study included 4 EMT markers, the EMT process also involves other 
transcription factors (TFs) which have been investigated in different cancers. Among these 
TFs, the most commonly studied include snail2, twist-1, twist-2, zeb-1, zeb-2 and fibronectin. 
Therefore, the expression profile of these markers should also be analysed when investigating 
EMT in CRC. Further, miRNA-21 targets various EMT-related proteins, among these are 
PDCD4, PTEN, SPRY2, RECK, TIAM1 and TIPM3. In addition, miRNA-34a also has 
numerous targets involved in EMT and the most common are notch1, notch2 and jagged1. It 
would thus be interesting to determine the expression profile of miRNA-21 and miRNA-34a 
together with these EMT related proteins. Furthermore, there are other tumour suppressor and 
oncogenic miRNAs involved in carcinogenesis. The most frequently investigated tumour 
suppressor miRNAs are the miRNA-34 (miRNA-34b and miRNA-34c) and miRNA-200 
families. Since most of the research that has been carried out on miRNA-34 family focuses on 
miRNA-34a, the expression of miRNA-34b and miRNA-34c in relation to EMT should also 
be explored. In addition, the oncomiRNA miRNA-155 is one of the most frequently studied 
miRNAs in cancer related studies. Therefore, in view of the fact that there is no published data 
on the role of miRNA-155 and EMT in our population, we suggest that these be investigated 
in CRC. Since this study included only 59 cases to determine the relationship between miRNA 
expression and EMT, we recommend that future studies use a larger sample size.  
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Appendices 
 
Appendix A: Clinicopathologic/demographic features of 100 CRC cases 
Case # 
Age 
(Y) Gender Grade 
Lymph 
nodes Stage 
Site of 
colon 
Part of 
colon 
        
1 65 Female 1 Yes IV Left Distal 
2 35 Female 3 No II Left Distal 
3 57 Female 1 Yes III Left Distal 
4 32 Female 1 Yes III Left Distal 
5 60 Female 3 Yes III Right Proximal 
6 56 Male 2 No I Right Proximal 
7 42 Male 1 No I Right Proximal 
8 62 Female 1 No III Left Distal 
9 51 Female 2 No I Left Distal 
10 83 Male 1 No III Left Distal 
11 65 Male 1 Yes IV Left Distal 
12 59 Male 2 Yes III Right Proximal 
13 65 Male 3 Yes III Right Proximal 
14 70 Female 2 Yes I Left Distal 
15 68 Male 2 No II Right Proximal 
16 51 Male 2 Yes III Left Distal 
17 52 Female 2 Yes III Left Distal 
18 50 Male 2 No I Left Distal 
19 72 Female 3 Yes III Right Proximal 
20 58 Male 2 No I Left Distal 
21 75 Female 1 No II Left Distal 
22 74 Male 2 No III Right Proximal 
23 50 Male 2 No III Left Distal 
24 59 Female 2 No I Right Proximal 
25 65 Female 2 No I Left Distal 
26 61 Female 2 No I Right Proximal 
27 51 Female 2 No IV Left Distal 
28 63 Female 2 No III Right Proximal 
29 60 Female 2 No I Left Distal 
30 70 Male 2 No III Right Proximal 
31 64 Male 2 No III Left Distal 
32 65 Male 2 No III Left Distal 
33 80 Male 2 No I Left Distal 
34 77 Male 2 No I Right Proximal 
35 55 Male 2 Yes III Left Distal 
36 60 Female 2 Yes IV Right Proximal 
37 73 Male 2 No II Right Proximal 
38 84 Female 2 No III Left Distal 
39 40 Male 2 No I Right Proximal 
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40 30 Female 2 No I Right Proximal 
41 76 Female 2 No III Right Proximal 
42 53 Female 3 Yes III Right Proximal 
43 83 Male 1 Yes III Right Proximal 
44 73 Female 3 Yes III Right Proximal 
45 84 Female 2 Yes III Left Distal 
46 71 Male 2 Yes III Right Proximal 
47 48 Male 2 No I Left Distal 
48 72 Female 2 No III Right Proximal 
49 68 Female 2 Yes IV Left Distal 
50 75 Female 2 Yes IV Right Proximal 
51 46 Female 2 No II Right Proximal 
52 30 Female 2 No II Right Proximal 
53 22 Male 2 Yes III Left Distal 
54 44 Male 1 Yes IV Right Proximal 
55 40 Female 1 Yes IV Right Proximal 
56 46 Female 3 No II Right Proximal 
57 29 Male 3 Yes III Left Distal 
58 30 Female 2 Yes III Right Proximal 
59 49 Female 2 No III Left Distal 
60 33 Female 2 No I Right Proximal 
61 56 Male 1 No I Right Proximal 
62 52 Female 1 No I Left Distal 
63 56 Male 3 Yes III Right Proximal 
64 64 Male 1 No II Left Distal 
65 70 Female 1 No II Left Distal 
66 59 Female 2 Yes III Right Proximal 
67 50 Female 1 No I Left Distal 
68 67 Female 2 Yes III Right Proximal 
69 70 Female 1 No I Left Distal 
70 58 Female 2 No II Left Distal 
71 69 Male 2 No II Left Distal 
72 67 Female 2 No I Right Proximal 
73 58 Female 2 No I Left Distal 
74 58 Female 2 No III Right Proximal 
75 70 Female 2 No I Left Distal 
76 50 Female 2 No I Left Distal 
77 80 Male 2 Yes III Left Distal 
78 62 Male 2 No IV Left Distal 
79 67 Male 2 No I Left Distal 
80 61 Female 2 No I Left Distal 
81 60 Male 2 Yes III Left Distal 
82 52 Female 2 No II Left Distal 
83 57 Female 2 No I Left Distal 
84 37 Female 2 No I Left Distal 
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85 71 Male 2 Yes III Left Distal 
86 66 Male 2 No I Left Distal 
87 61 Female 2 No I Left Distal 
88 68 Male 2 No III Left Distal 
89 68 Female 1 Yes III Right Proximal 
90 66 Female 3 Yes III Right Proximal 
91 73 Male 1 Yes III Right Proximal 
92 80 Female 1 Yes III Left Distal 
93 61 Male 2 No I Right Proximal 
94 26 Male 2 No III Right Proximal 
95 57 Female 2 No II Left Distal 
96 67 Male 2 No I Left Distal 
97 72 Male 2 Yes III Right Proximal 
98 67 Female 1 No III Right Proximal 
99 51 Male 1 No II Left Distal 
100 59 Female 2 No I Left Proximal 
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Appendix B: IHC results of EMT markers  
Case # Snail-1 E-cadherin  Vimentin CD44v6 
 N-
cadherin 
1 0 1 0 1  0 
2 0 0 1 0  0 
3 0 0 0 0  0 
4 0 0 0 0  0 
5 0 0 0 0  0 
6 1 0 0 0  0 
7 0 0 0 0  0 
8 0 0 0 0  0 
9 1 0 0 0  0 
10 1 0 0 0  0 
11 0 0 0 0  0 
12 0 0 0 0  0 
13 0 0 0 0  0 
14 0 0 0 0  0 
15 0 0 0 0  0 
16 0 0 0 0  0 
17 1 0 0 0  0 
18 0 0 0 1  0 
19 0 0 0 0  0 
20 0 1 0 0  0 
21 0 1 0 0  0 
22 0 0 0 0  0 
23 0 0 0 0  0 
24 0 0 0 0  0 
25 0 0 0 0  0 
26 0 0 0 0  0 
27 0 1 0 1  0 
28 1 0 0 0  0 
29 0 0 0 0  0 
30 0 0 0 0  0 
31 0 0 0 0  0 
32 0 0 0 0  0 
33 0 1 0 0  0 
34 0 0 0 0  0 
35 1 1 0 0  0 
36 0 1 0 1  1 
37 0 0 0 0  0 
38 0 0 0 1  0 
39 0 0 0 0  0 
40 0 0 0 0  0 
41 0 0 0 0  0 
42 0 0 0 1  0 
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43 1 0 0 1  0 
44 0 0 0 1  0 
45 0 0 0 0  1 
46 0 0 0 0  0 
47 0 1 0 0  0 
48 0 0 0 1  0 
49 0 0 0 0  1 
50 0 1 0 1  0 
51 0 0 0 0  0 
52 0 1 0 0  0 
53 0 0 0 1  0 
54 0 0 0 0  0 
55 0 0 0 0  0 
56 0 0 0 0  0 
57 0 0 0 0  0 
58 0 1 0 1  0 
59 0 0 0 0  0 
60 0 0 1 1  0 
61 1 0 0 0  0 
62 1 1 0 0  0 
63 1 0 0 1  0 
64 1 1 0 0  0 
65 1 0 0 0  0 
66 1 0 0 0  0 
67 1 0 0 0  0 
68  0 0 0 1  0 
69 0 0 0 0  0 
70 0 0 0 1  0 
71 1 0 0 1  0 
72 1 1 0 0  0 
73 1 0 0 0  0 
74 0 0 0 0  0 
75 1 0 0 0  0 
76 1 0 0 0  0 
77 1 0 0 1  0 
78 1 0 0 1  0 
79 0 0 0 1  0 
80 1 1 0 0  0 
81 1 1 0 1  0 
82 0 0 0 1  0 
83 0 1 0 0  0 
84 0 0 0 1  0 
85 1 1 0 0  0 
86 1 0 0 0  0 
87 1 1 0 0  0 
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88 1 0 0 0  0 
89 0 0 0 1  0 
90 1 0 0 0  0 
91 1 0 0 1  0 
92 1 0 0 0  0 
93 1 0 0 1  0 
94 1 1 0 1  0 
95 0 0 0 0  0 
96 0 0 0 1  0 
97 1 1 0 0  0 
98 1 1 0 1  0 
99 0 0 0 1  0 
100 1 1 0 0  0 
Expression 
level 
Positive 
expression = 1     
 
 
  
Negative 
expression = 0     
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Appendix C: CRCs with EMT features with an asterisk (*) 
Case # Snail-1 E-cadherin  Vimentin N-cadherin 
1 0 1 0 0 
2* 0 0 1 0 
3 0 0 0 0 
4 0 0 0 0 
5 0 0 0 0 
6* 1 0 0 0 
7 0 0 0 0 
8 0 0 0 0 
9* 1 0 0 0 
10* 1 0 0 0 
11 0 0 0 0 
12 0 0 0 0 
13 0 0 0 0 
14 0 0 0 0 
15 0 0 0 0 
16 0 0 0 0 
17* 1 0 0 0 
18 0 0 0 0 
19 0 0 0 0 
20 0 1 0 0 
21 0 1 0 0 
22 0 0 0 0 
23 0 0 0 0 
24 0 0 0 0 
25 0 0 0 0 
26 0 0 0 0 
27 0 1 0 0 
28* 1 0 0 0 
29 0 0 0 0 
30 0 0 0 0 
31 0 0 0 0 
32 0 0 0 0 
33 0 1 0 0 
34 0 0 0 0 
35 1 1 0 0 
36 0 1 0 1 
37 0 0 0 0 
38 0 0 0 0 
39 0 0 0 0 
40 0 0 0 0 
41 0 0 0 0 
42 0 0 0 0 
43* 1 0 0 0 
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44 0 0 0 0 
45 0 0 0 0 
46 0 0 0 0 
47 0 1 0 0 
48 0 0 0 0 
49* 0 0 0 1 
50 0 1 0 0 
51 0 0 0 0 
52 0 1 0 0 
53 0 0 0 0 
54 0 0 0 0 
55 0 0 0 0 
56 0 0 0 0 
57 0 0 0 0 
58 0 1 0 0 
59 0 0 0 0 
60* 0 0 1 0 
61* 1 0 0 0 
62 1 1 0 0 
63* 1 0 0 0 
64 1 1 0 0 
65* 1 0 0 0 
66* 1 0 0 0 
67* 1 0 0 0 
68  0 0 0 0 
69 0 0 0 0 
70 0 0 0 0 
71* 1 0 0 0 
72 1 1 0 0 
73* 1 0 0 0 
74 0 0 0 0 
75* 1 0 0 0 
76* 1 0 0 0 
77* 1 0 0 0 
78* 1 0 0 0 
79 0 0 0 0 
80 1 1 0 0 
81 1 1 0 0 
82 0 0 0 0 
83 0 1 0 0 
84 0 0 0 0 
85 1 1 0 0 
86* 1 0 0 0 
87 1 1 0 0 
88* 1 0 0 0 
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89 0 0 0 0 
90* 1 0 0 0 
91* 1 0 0 0 
92* 1 0 0 0 
93* 1 0 0 0 
94 1 1 0 0 
95 0 0 0 0 
96 0 0 0 0 
97 1 1 0 0 
98 1 1 0 0 
99* 1 0 0 0 
100 0 1 0 0 
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Appendix D: miRNA-21 and miRNA-34a -2ddcp expression values in 59 tumour 
tissues 
Case 
no 
miRNA-21 -2ddcp 
values 
miRNA-34a -2ddcp 
values 
1 0.447213595 0.280468849 
2 0.502023 0.182773446 
3 0.505782 0.331430488 
4 7.027001 0.838618726 
5 9.0238735 1.20701056 
6 0.596356 0.688688455 
7 0.510841 0.473401541 
8 0.503467 0.217925202 
9 0.512678 1.32951693 
10 0.506518 1.443056262 
11 4.899042 0.588166955 
12 3.99943 0.158456149 
13 5.39534 1.017750413 
14 4.628848 0.345367275 
15 4.3301979 0.43677141 
16 5.382973 0.580359269 
17 5.484393 0.323945954 
18 4.587338 0.193766307 
19 4.133446 0.252642727 
20 8.300245 0.200699564 
21 8.029385 0.944751395 
22 14.9832 0.665716566 
23 3.501831 0.101613809 
24 7.606248 0.318078445 
25 20.91673 1.765707235 
26 3.6180475 0.456919499 
27 14.2789265 0.51354166 
28 5.4454695 1.849142609 
29 8.3768305 1.016415872 
30 3.3756825 0.229260366 
31 12.270527 1.020448018 
32 12.3269725 1.152470835 
33 24.7672275 1.165962335 
34 19.240004 0.545858088 
35 16.648958 0.637157847 
36 9.6353965 0.589193781 
37 5.5076065 0.432940109 
38 36.1316705 0.845930629 
39 1.6044055 1.147455517 
40 2.7000315 1.754503694 
41 3.1607275 1.364754109 
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42 3.075691 2.006186649 
43 2.5976345 1.738816443 
44 6.7991015 0.768621111 
45 0.488852 0.130960242 
46 2.65453 2.489502461 
47 2.278889 0.602505907 
48 1.5174885 1.771025739 
49 0.964083 0.184000227 
50 2.39092595 0.51494735 
51 2.983348 0.995246438 
52 3.147416 1.454929754 
53 1.071846 0.132396105 
54 1.4904435 0.588134276 
55 3.287223 0.532664002 
56 0.845712 0.094732946 
57 1.763033 1.195004624 
58 0.5734565 0.758293183 
59 2.521214 1.010833897 
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Appendix E: miRNA-21 and miRNA-34a -2ddcp expression values in 12 normal 
tissues 
 
Case # 
miRNA-21 -2ddcp 
values (cut off = 2.6) 
miRNA-34a -2ddcp 
values (cut off = 0.22) 
6 3.361301004 4.680650502 
8 1.739598153 4.869799077 
12 0.125462237 6.062731119 
17 0.219076781 8.60953839 
19 3.733035337 11.36651767 
23 0.355793881 11.67789694 
39 0.398609075 19.69930454 
44 1.027698902 22.51384945 
45 0.469944152 22.73497208 
56 0.517211096 28.25860555 
57 4.15103009 30.57551505 
59 15.04413379 37.0220669 
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Appendix F: IHC results of mismatch repair proteins  
Case # MLH1 MSH2 MSH6 
1 Present Present Present 
2 Present Present Present 
3 Present Present Present 
4 Present Present Present 
5 Present Present Absent 
6 Present Present Present 
7 Present Absent Absent 
8 Present Present Present 
9 Present Present Present 
10 Present Present Present 
11 Present Present Present 
12 Present Present Present 
13 Present Present Present 
14 Present Present Present 
15 Present Present Present 
16 Present Present Present 
17 Present Present Present 
18 Present Absent Present 
19 Present Present Present 
20 Present Present Present 
21 Present Present Present 
22 Present Present Absent 
23 Present Absent Present 
24 Present Present Present 
25 Present Present Present 
26 Absent Absent Absent 
27 Present Present Present 
28 Absent Present Present 
29 Present Present Present 
30 Present Present Present 
31 Present Present Present 
32 Present Present Absent 
33 Present Absent Absent 
34 Present Present Present 
35 Present Present Present 
36 Present Present Present 
37 Present Present Present 
38 Present Present Present 
39 Present Present Present 
40 Present Present Present 
41 Present Present Present 
42 Absent 
Cannot 
interpret 
Cannot 
interpret  
 131 
 
43 Absent Present Present 
44 Absent Present Present 
45 Present Present Present 
46 Present Present Present 
47 Present Present Present 
48 Present Present Present 
49 Present Present Present 
50 Present Present Present 
51 Absent Present Absent 
52 Absent Present Present 
53 Present Present Present 
54 Absent Absent Absent 
55 Present Absent Absent 
56 Absent Present Present 
57 Absent Absent Absent 
58 Absent Present Present 
59 Absent Present Absent 
Total: 20 MSI tumours 
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Appendix G: miRNA-21 expression in 20 MSI tumours 
 
Average of -2ddcp = 3.5 (cut off value) 
Case # 
miRNA-21 
expression 
miRNA-21 -2ddcp 
values 
5 H 9.0238735 
7 L 0.510841 
18 H 4.587338 
22 H 14.9832 
23 H 3.501831 
26 H 3.6180475 
32 H 12.3269725 
33 H 24.7672275 
51 L 2.983348 
52 L 3.147416 
54 L 1.4904435 
55 L 3.287223 
56 L 0.845712 
57 L 1.763033 
58 L 0.5734565 
59 L 2.521214 
28 H 5.4454695 
42 L 3.075691 
43 L 2.5976345 
44 H 6.7991015 
H = High 
expression  9/20 (45%)   
L = Low 
expression  11/20 (55%)   
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Appendix H: miRNA-21 expression in 39 MSS tumours 
 
Average of -2ddcp = 3.5 (cut off value) 
Case # 
miRNA- 21 
expression 
miRNA-21 -2ddcp 
values 
1 L 0.447213595 
2 L 0.502023 
3 L 0.505782 
4 H 7.027001 
6 L 0.596356 
8 L 0.503467 
9 L 0.512678 
10 L 0.506518 
11 H 4.899042 
12 H 3.99943 
13 H 5.39534 
14 H 4.628848 
15 H 4.3301979 
16 H 5.382973 
17 H 5.484393 
19 H 4.133446 
20 H 8.300245 
21 H 8.029385 
24 H 7.606248 
25 H 20.91673 
27 H 14.2789265 
29 H 8.3768305 
30 H 3.3756825 
31 H 12.270527 
34 H 19.240004 
35 H 16.648958 
36 H 9.6353965 
37 H 5.5076065 
38 H 36.1316705 
39 L 1.6044055 
40 L 2.7000315 
41 L 3.1607275 
45 L 0.488852 
46 L 2.65453 
47 L 2.278889 
48 L 1.5174885 
49 L 0.964083 
50 L 2.39092595 
 53  L  1.071846 
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H = High 
expression  22/39 (56.4%)   
L = Low 
expression  17/39 (43.6%)   
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Appendix I: miRNA-34a expression in 20 MSI tumours 
 
Average of -2ddcp = 0.6 (cut off value) 
Case # 
miRNA-34a 
expression 
miRNA-34a -
2ddcp 
5 H 0.688688455 
7 H 1.32951693 
18 H 0.944751395 
22 H 1.849142609 
23 H 1.016415872 
26 L 0.545858088 
28 L 0.589193781 
32 H 1.754503694 
33 H 1.364754109 
42 L 0.51494735 
43 H 0.995246438 
44 H 1.454929754 
51 H 1.010833897 
52 H 1.20701056 
54 L 0.193766307 
55 H 0.665716566 
56 L 0.101613809 
57 L 0.456919499 
58 H 1.152470835 
59 H 1.165962335 
H = High 
expression 14/20 (70%)   
L = Low 
expression  6/20 (30%)   
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Appendix J: miRNA-34a expression in 39 MSS tumours 
 
Average of -2ddcp = 0.6 (cut off value) 
Case # 
miRNA-34a 
expression 
miRNA-34a -
2ddcp 
1 L 0.280468849 
2 L 0.182773446 
3 L 0.331430488 
4 H 0.838618726 
6 L 0.217925202 
8 H 1.443056262 
9 L 0.588166955 
10 L 0.158456149 
11 H 1.017750413 
12 L 0.345367275 
13 L 0.43677141 
14 L 0.580359269 
15 L 0.323945954 
16 L 0.252642727 
17 L 0.200699564 
19 L 0.318078445 
20 H 1.765707235 
21 L 0.51354166 
24 L 0.229260366 
25 H 1.020448018 
27 H 0.637157847 
29 L 0.432940109 
30 H 0.845930629 
31 H 1.147455517 
34 H 2.006186649 
35 H 1.738816443 
36 H 0.768621111 
37 L 0.130960242 
38 H 2.489502461 
39 H 0.602505907 
40 H 1.771025739 
41 L 0.184000227 
45 L 0.132396105 
46 L 0.588134276 
47 L 0.532664002 
48 L 0.094732946 
49 H 1.195004624 
50 H 0.758293183 
53 L 0.132396105 
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H = High 
expression 16/39 (41%)   
L = Low 
expression 23/39 (59%)   
 
 
 
 
 
 
Appendix K: miRNA-21 expression vs age in the 12 normal tissues 
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Appendix L: EMT/stem cell markers vs clinicopathologic features (Stata 12 data)  
 
(I) E-cadherin:  
 
 
 
 
  
 
           Fisher's exact =                 0.263
          Pearson chi2(3) =   3.9459   Pr = 0.267
                100.00     100.00     100.00     100.00      100.00 
                  33.0       14.0       44.0        9.0       100.0 
     Total          33         14         44          9         100 
                                                                   
                 27.27      21.43      15.91      44.44       23.00 
                   7.6        3.2       10.1        2.1        23.0 
         1           9          3          7          4          23 
                                                                   
                 72.73      78.57      84.09      55.56       77.00 
                  25.4       10.8       33.9        6.9        77.0 
         0          24         11         37          5          77 
                                                                   
 ecadherin           I         II        III         IV       Total
                                stage
           Fisher's exact =                 0.189
          Pearson chi2(2) =   3.4504   Pr = 0.178
                100.00     100.00     100.00      100.00 
                  22.0       68.0       10.0       100.0 
     Total          22         68         10         100 
                                                        
                 22.73      26.47       0.00       23.00 
                   5.1       15.6        2.3        23.0 
         1           5         18          0          23 
                                                        
                 77.27      73.53     100.00       77.00 
                  16.9       52.4        7.7        77.0 
         0          17         50         10          77 
                                                        
 ecadherin           1          2          3       Total
                          grade
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   1-sided Fisher's exact =                 0.548
           Fisher's exact =                 1.000
          Pearson chi2(1) =   0.0192   Pr = 0.890
                100.00     100.00      100.00 
                  64.0       36.0       100.0 
     Total          64         36         100 
                                             
                 23.44      22.22       23.00 
                  14.7        8.3        23.0 
         1          15          8          23 
                                             
                 76.56      77.78       77.00 
                  49.3       27.7        77.0 
         0          49         28          77 
                                             
 ecadherin          No        Yes       Total
              lymphnodemetastasis
. 
   1-sided Fisher's exact =                 0.220
           Fisher's exact =                 0.347
          Pearson chi2(1) =   1.0299   Pr = 0.310
                100.00     100.00      100.00 
                  56.0       44.0       100.0 
     Total          56         44         100 
                                             
                 26.79      18.18       23.00 
                  12.9       10.1        23.0 
         1          15          8          23 
                                             
                 73.21      81.82       77.00 
                  43.1       33.9        77.0 
         0          41         36          77 
                                             
 ecadherin        Left      Right       Total
                  siteofcolon
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   1-sided Fisher's exact =                 0.428
           Fisher's exact =                 0.811
          Pearson chi2(1) =   0.1825   Pr = 0.669
                100.00     100.00      100.00 
                  57.0       43.0       100.0 
     Total          57         43         100 
                                             
                 24.56      20.93       23.00 
                  13.1        9.9        23.0 
         1          14          9          23 
                                             
                 75.44      79.07       77.00 
                  43.9       33.1        77.0 
         0          43         34          77 
                                             
 ecadherin      Female       Male       Total
                    gender
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(II) Snail-1:  
 
 
 
 
 
 
. 
           Fisher's exact =                 0.344
          Pearson chi2(6) =   5.8769   Pr = 0.437
                100.00     100.00     100.00     100.00      100.00 
                  33.0       14.0       44.0        9.0       100.0 
     Total          33         14         44          9         100 
                                                                   
                  0.00       0.00       2.27       0.00        1.00 
                   0.3        0.1        0.4        0.1         1.0 
         0           0          0          1          0           1 
                                                                   
                 42.42      21.43      38.64      11.11       35.00 
                  11.6        4.9       15.4        3.1        35.0 
         1          14          3         17          1          35 
                                                                   
                 57.58      78.57      59.09      88.89       64.00 
                  21.1        9.0       28.2        5.8        64.0 
         0          19         11         26          8          64 
                                                                   
    snail1           I         II        III         IV       Total
                                stage
           Fisher's exact =                 0.583
          Pearson chi2(4) =   2.5399   Pr = 0.638
                100.00     100.00     100.00      100.00 
                  22.0       68.0       10.0       100.0 
     Total          22         68         10         100 
                                                        
                  0.00       1.47       0.00        1.00 
                   0.2        0.7        0.1         1.0 
         0           0          1          0           1 
                                                        
                 45.45      33.82      20.00       35.00 
                   7.7       23.8        3.5        35.0 
         1          10         23          2          35 
                                                        
                 54.55      64.71      80.00       64.00 
                  14.1       43.5        6.4        64.0 
         0          12         44          8          64 
                                                        
    snail1           1          2          3       Total
                          grade
stage 1:  enumerations = 0
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           Fisher's exact =                 0.538
          Pearson chi2(2) =   1.8225   Pr = 0.402
                100.00     100.00      100.00 
                  64.0       36.0       100.0 
     Total          64         36         100 
                                             
                  0.00       2.78        1.00 
                   0.6        0.4         1.0 
         0           0          1           1 
                                             
                 35.94      33.33       35.00 
                  22.4       12.6        35.0 
         1          23         12          35 
                                             
                 64.06      63.89       64.00 
                  41.0       23.0        64.0 
         0          41         23          64 
                                             
    snail1          No        Yes       Total
              lymphnodemetastasis
           Fisher's exact =                 0.291
          Pearson chi2(2) =   2.1553   Pr = 0.340
                100.00     100.00      100.00 
                  56.0       44.0       100.0 
     Total          56         44         100 
                                             
                  0.00       2.27        1.00 
                   0.6        0.4         1.0 
         0           0          1           1 
                                             
                 39.29      29.55       35.00 
                  19.6       15.4        35.0 
         1          22         13          35 
                                             
                 60.71      68.18       64.00 
                  35.8       28.2        64.0 
         0          34         30          64 
                                             
    snail1        Left      Right       Total
                  siteofcolon
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           Fisher's exact =                 0.337
          Pearson chi2(2) =   2.1737   Pr = 0.337
                100.00     100.00      100.00 
                  57.0       43.0       100.0 
     Total          57         43         100 
                                             
                  1.75       0.00        1.00 
                   0.6        0.4         1.0 
         0           1          0           1 
                                             
                 29.82      41.86       35.00 
                  19.9       15.1        35.0 
         1          17         18          35 
                                             
                 68.42      58.14       64.00 
                  36.5       27.5        64.0 
         0          39         25          64 
                                             
    snail1      Female       Male       Total
                    gender
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(III) Vimentin: 
 
 
 
 
 
  
 
           Fisher's exact =                 0.284
          Pearson chi2(3) =   3.1496   Pr = 0.369
                100.00     100.00     100.00     100.00      100.00 
                  33.0       14.0       44.0        9.0       100.0 
     Total          33         14         44          9         100 
                                                                   
                  3.03       7.14       0.00       0.00        2.00 
                   0.7        0.3        0.9        0.2         2.0 
         1           1          1          0          0           2 
                                                                   
                 96.97      92.86     100.00     100.00       98.00 
                  32.3       13.7       43.1        8.8        98.0 
         0          32         13         44          9          98 
                                                                   
  vimentin           I         II        III         IV       Total
                                stage
. 
           Fisher's exact =                 0.238
          Pearson chi2(2) =   3.8115   Pr = 0.149
                100.00     100.00     100.00      100.00 
                  22.0       68.0       10.0       100.0 
     Total          22         68         10         100 
                                                        
                  0.00       1.47      10.00        2.00 
                   0.4        1.4        0.2         2.0 
         1           0          1          1           2 
                                                        
                100.00      98.53      90.00       98.00 
                  21.6       66.6        9.8        98.0 
         0          22         67          9          98 
                                                        
  vimentin           1          2          3       Total
                          grade
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   1-sided Fisher's exact =                 0.407
           Fisher's exact =                 0.535
          Pearson chi2(1) =   1.1480   Pr = 0.284
                100.00     100.00      100.00 
                  64.0       36.0       100.0 
     Total          64         36         100 
                                             
                  3.13       0.00        2.00 
                   1.3        0.7         2.0 
         1           2          0           2 
                                             
                 96.88     100.00       98.00 
                  62.7       35.3        98.0 
         0          62         36          98 
                                             
  vimentin          No        Yes       Total
              lymphnodemetastasis
. 
   1-sided Fisher's exact =                 0.689
           Fisher's exact =                 1.000
          Pearson chi2(1) =   0.0298   Pr = 0.863
                100.00     100.00      100.00 
                  56.0       44.0       100.0 
     Total          56         44         100 
                                             
                  1.79       2.27        2.00 
                   1.1        0.9         2.0 
         1           1          1           2 
                                             
                 98.21      97.73       98.00 
                  54.9       43.1        98.0 
         0          55         43          98 
                                             
  vimentin        Left      Right       Total
                  siteofcolon
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. 
   1-sided Fisher's exact =                 0.322
           Fisher's exact =                 0.505
          Pearson chi2(1) =   1.5396   Pr = 0.215
                100.00     100.00      100.00 
                  57.0       43.0       100.0 
     Total          57         43         100 
                                             
                  3.51       0.00        2.00 
                   1.1        0.9         2.0 
         1           2          0           2 
                                             
                 96.49     100.00       98.00 
                  55.9       42.1        98.0 
         0          55         43          98 
                                             
  vimentin      Female       Male       Total
                    gender
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(IV) N-cadherin: 
 
 
 
 
 
  
 
           Fisher's exact =                 0.007
          Pearson chi2(3) =  20.6349   Pr = 0.000
                100.00     100.00     100.00     100.00      100.00 
                  33.0       14.0       44.0        9.0       100.0 
     Total          33         14         44          9         100 
                                                                   
                  0.00       0.00       0.00      22.22        2.00 
                   0.7        0.3        0.9        0.2         2.0 
         1           0          0          0          2           2 
                                                                   
                100.00     100.00     100.00      77.78       98.00 
                  32.3       13.7       43.1        8.8        98.0 
         0          33         14         44          7          98 
                                                                   
 ncadherin           I         II        III         IV       Total
                                stage
           Fisher's exact =                 1.000
          Pearson chi2(2) =   0.9604   Pr = 0.619
                100.00     100.00     100.00      100.00 
                  22.0       68.0       10.0       100.0 
     Total          22         68         10         100 
                                                        
                  0.00       2.94       0.00        2.00 
                   0.4        1.4        0.2         2.0 
         1           0          2          0           2 
                                                        
                100.00      97.06     100.00       98.00 
                  21.6       66.6        9.8        98.0 
         0          22         66         10          98 
                                                        
 ncadherin           1          2          3       Total
                          grade
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   1-sided Fisher's exact =                 0.127
           Fisher's exact =                 0.127
          Pearson chi2(1) =   3.6281   Pr = 0.057
                100.00     100.00      100.00 
                  64.0       36.0       100.0 
     Total          64         36         100 
                                             
                  0.00       5.56        2.00 
                   1.3        0.7         2.0 
         1           0          2           2 
                                             
                100.00      94.44       98.00 
                  62.7       35.3        98.0 
         0          64         34          98 
                                             
 ncadherin          No        Yes       Total
              lymphnodemetastasis
   1-sided Fisher's exact =                 0.689
           Fisher's exact =                 1.000
          Pearson chi2(1) =   0.0298   Pr = 0.863
                100.00     100.00      100.00 
                  56.0       44.0       100.0 
     Total          56         44         100 
                                             
                  1.79       2.27        2.00 
                   1.1        0.9         2.0 
         1           1          1           2 
                                             
                 98.21      97.73       98.00 
                  54.9       43.1        98.0 
         0          55         43          98 
                                             
 ncadherin        Left      Right       Total
                  siteofcolon
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   1-sided Fisher's exact =                 0.322
           Fisher's exact =                 0.505
          Pearson chi2(1) =   1.5396   Pr = 0.215
                100.00     100.00      100.00 
                  57.0       43.0       100.0 
     Total          57         43         100 
                                             
                  3.51       0.00        2.00 
                   1.1        0.9         2.0 
         1           2          0           2 
                                             
                 96.49     100.00       98.00 
                  55.9       42.1        98.0 
         0          55         43          98 
                                             
 ncadherin      Female       Male       Total
                    gender
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(V) CD44v6: 
 
 
 
 
 
  
 
           Fisher's exact =                 0.150
          Pearson chi2(3) =   5.3580   Pr = 0.147
                100.00     100.00     100.00     100.00      100.00 
                  33.0       14.0       44.0        9.0       100.0 
     Total          33         14         44          9         100 
                                                                   
                 18.18      28.57      34.09      55.56       30.00 
                   9.9        4.2       13.2        2.7        30.0 
         1           6          4         15          5          30 
                                                                   
                 81.82      71.43      65.91      44.44       70.00 
                  23.1        9.8       30.8        6.3        70.0 
         0          27         10         29          4          70 
                                                                   
    cd44v6           I         II        III         IV       Total
                                stage
. 
           Fisher's exact =                 1.000
          Pearson chi2(2) =   0.1031   Pr = 0.950
                100.00     100.00     100.00      100.00 
                  22.0       68.0       10.0       100.0 
     Total          22         68         10         100 
                                                        
                 27.27      30.88      30.00       30.00 
                   6.6       20.4        3.0        30.0 
         1           6         21          3          30 
                                                        
                 72.73      69.12      70.00       70.00 
                  15.4       47.6        7.0        70.0 
         0          16         47          7          70 
                                                        
    cd44v6           1          2          3       Total
                          grade
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   1-sided Fisher's exact =                 0.110
           Fisher's exact =                 0.175
          Pearson chi2(1) =   2.1164   Pr = 0.146
                100.00     100.00      100.00 
                  64.0       36.0       100.0 
     Total          64         36         100 
                                             
                 25.00      38.89       30.00 
                  19.2       10.8        30.0 
         1          16         14          30 
                                             
                 75.00      61.11       70.00 
                  44.8       25.2        70.0 
         0          48         22          70 
                                             
    cd44v6          No        Yes       Total
              lymphnodemetastasis
   1-sided Fisher's exact =                 0.283
           Fisher's exact =                 0.511
          Pearson chi2(1) =   0.6262   Pr = 0.429
                100.00     100.00      100.00 
                  56.0       44.0       100.0 
     Total          56         44         100 
                                             
                 26.79      34.09       30.00 
                  16.8       13.2        30.0 
         1          15         15          30 
                                             
                 73.21      65.91       70.00 
                  39.2       30.8        70.0 
         0          41         29          70 
                                             
    cd44v6        Left      Right       Total
                  siteofcolon
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. 
   1-sided Fisher's exact =                 0.394
           Fisher's exact =                 0.664
          Pearson chi2(1) =   0.2351   Pr = 0.628
                100.00     100.00      100.00 
                  57.0       43.0       100.0 
     Total          57         43         100 
                                             
                 28.07      32.56       30.00 
                  17.1       12.9        30.0 
         1          16         14          30 
                                             
                 71.93      67.44       70.00 
                  39.9       30.1        70.0 
         0          41         29          70 
                                             
    cd44v6      Female       Male       Total
                    gender
 153 
 
Appendix M: Relationship between E-cadherin and mesenchymal/stem cell markers 
(Stata 12 data) 
 
(I) E-cadherin vs N-cadherin: 
 
 
 
 
(II) E-cadherin vs Snail-1: 
 
 
 
 
 
 
 
 
   1-sided Fisher's exact =                 0.409
           Fisher's exact =                 0.409
          Pearson chi2(1) =   0.8401   Pr = 0.359
                100.00     100.00      100.00 
                  98.0        2.0       100.0 
     Total          98          2         100 
                                             
                 22.45      50.00       23.00 
                  22.5        0.5        23.0 
         1          22          1          23 
                                             
                 77.55      50.00       77.00 
                  75.5        1.5        77.0 
         0          76          1          77 
                                             
 ecadherin           0          1       Total
                   ncadherin
           Fisher's exact =                 0.134
          Pearson chi2(2) =   4.0368   Pr = 0.133
                100.00     100.00     100.00      100.00 
                  64.0       35.0        1.0       100.0 
     Total          64         35          1         100 
                                                        
                 17.19      34.29       0.00       23.00 
                  14.7        8.1        0.2        23.0 
         1          11         12          0          23 
                                                        
                 82.81      65.71     100.00       77.00 
                  49.3       26.9        0.8        77.0 
         0          53         23          1          77 
                                                        
 ecadherin           0          1          0       Total
                          snail1
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(III) E-cadherin vs Vimentin: 
 
 
 
 
 
(IV) E-cadherin vs CD44v6 
 
 
 
 
 
 
 
. 
   1-sided Fisher's exact =                 0.591
           Fisher's exact =                 1.000
          Pearson chi2(1) =   0.6096   Pr = 0.435
                100.00     100.00      100.00 
                  98.0        2.0       100.0 
     Total          98          2         100 
                                             
                 23.47       0.00       23.00 
                  22.5        0.5        23.0 
         1          23          0          23 
                                             
                 76.53     100.00       77.00 
                  75.5        1.5        77.0 
         0          75          2          77 
                                             
 ecadherin           0          1       Total
                   vimentin
   1-sided Fisher's exact =                 0.372
           Fisher's exact =                 0.609
          Pearson chi2(1) =   0.3253   Pr = 0.568
                100.00     100.00      100.00 
                  70.0       30.0       100.0 
     Total          70         30         100 
                                             
                 21.43      26.67       23.00 
                  16.1        6.9        23.0 
         1          15          8          23 
                                             
                 78.57      73.33       77.00 
                  53.9       23.1        77.0 
         0          55         22          77 
                                             
 ecadherin           0          1       Total
                    cd44v6
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Appendix N: Relationship between CD44v6 and EMT markers (Stata 12 data) 
 
(I) CD44v6 vs E-cadherin: 
 
 
 
(II) CD44v6 vs N-cadherin 
 
 
 
 
 
 
 
 
 
 
 
   1-sided Fisher's exact =                 0.372
           Fisher's exact =                 0.609
          Pearson chi2(1) =   0.3253   Pr = 0.568
                100.00     100.00      100.00 
                  77.0       23.0       100.0 
     Total          77         23         100 
                                             
                 28.57      34.78       30.00 
                  23.1        6.9        30.0 
         1          22          8          30 
                                             
                 71.43      65.22       70.00 
                  53.9       16.1        70.0 
         0          55         15          70 
                                             
    cd44v6           0          1       Total
                   ecadherin
   1-sided Fisher's exact =                 0.512
           Fisher's exact =                 0.512
          Pearson chi2(1) =   0.3887   Pr = 0.533
                100.00     100.00      100.00 
                  98.0        2.0       100.0 
     Total          98          2         100 
                                             
                 29.59      50.00       30.00 
                  29.4        0.6        30.0 
         1          29          1          30 
                                             
                 70.41      50.00       70.00 
                  68.6        1.4        70.0 
         0          69          1          70 
                                             
    cd44v6           0          1       Total
                   ncadherin
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(III) CD44v6 vs Snail-1: 
 
 
 
 
(IV) CD44v6 vs Vimentin: 
 
 
 
 
 
 
 
 
 
           Fisher's exact =                 0.419
          Pearson chi2(2) =   2.3703   Pr = 0.306
                100.00     100.00     100.00      100.00 
                  64.0       35.0        1.0       100.0 
     Total          64         35          1         100 
                                                        
                 29.69      28.57     100.00       30.00 
                  19.2       10.5        0.3        30.0 
         1          19         10          1          30 
                                                        
                 70.31      71.43       0.00       70.00 
                  44.8       24.5        0.7        70.0 
         0          45         25          0          70 
                                                        
    cd44v6           0          1          0       Total
                          snail1
   1-sided Fisher's exact =                 0.512
           Fisher's exact =                 0.512
          Pearson chi2(1) =   0.3887   Pr = 0.533
                100.00     100.00      100.00 
                  98.0        2.0       100.0 
     Total          98          2         100 
                                             
                 29.59      50.00       30.00 
                  29.4        0.6        30.0 
         1          29          1          30 
                                             
                 70.41      50.00       70.00 
                  68.6        1.4        70.0 
         0          69          1          70 
                                             
    cd44v6           0          1       Total
                   vimentin
 157 
 
Appendix O: E-cadherin expression in stages 3 and 4 versus other stages 
 
E-cadherin expression: Stage 1 vs Stage 4 
 
 
 
 
E-cadherin expression: Stage 2 vs Stage 4 
 
 
 
 
 
 
 
 
   1-sided Fisher's exact =                 0.179
           Fisher's exact =                 0.290
          Pearson chi2(1) =   2.2098   Pr = 0.137
                100.00     100.00      100.00 
                  28.0        5.0        33.0 
     Total          28          5          33 
                                             
                 32.14       0.00       27.27 
                   7.6        1.4         9.0 
         1           9          0           9 
                                             
                 67.86     100.00       72.73 
                  20.4        3.6        24.0 
         0          19          5          24 
                                             
    stage1           0          1       Total
                    stage4
   1-sided Fisher's exact =                 0.786
           Fisher's exact =                 1.000
          Pearson chi2(1) =   0.2937   Pr = 0.588
                100.00     100.00      100.00 
                  13.0        1.0        14.0 
     Total          13          1          14 
                                             
                 23.08       0.00       21.43 
                   2.8        0.2         3.0 
         1           3          0           3 
                                             
                 76.92     100.00       78.57 
                  10.2        0.8        11.0 
         0          10          1          11 
                                             
    stage2           0          1       Total
                    stage4
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E-cadherin expression: Stage 3 vs Stage 4 
 
 
 
 
E-cadherin expression: Stage 1 vs Stage 3 
 
 
 
 
 
 
 
 
 
 
 
   1-sided Fisher's exact =                 0.296
           Fisher's exact =                 0.378
          Pearson chi2(1) =   0.9289   Pr = 0.335
                100.00     100.00      100.00 
                  31.0       12.0        43.0 
     Total          31         12          43 
                                             
                 12.90      25.00       16.28 
                   5.0        2.0         7.0 
         1           4          3           7 
                                             
                 87.10      75.00       83.72 
                  26.0       10.0        36.0 
         0          27          9          36 
                                             
    stage3           0          1       Total
                    stage4
   1-sided Fisher's exact =                 0.705
           Fisher's exact =                 1.000
          Pearson chi2(1) =   0.0119   Pr = 0.913
                100.00     100.00      100.00 
                  29.0        4.0        33.0 
     Total          29          4          33 
                                             
                 27.59      25.00       27.27 
                   7.9        1.1         9.0 
         1           8          1           9 
                                             
                 72.41      75.00       72.73 
                  21.1        2.9        24.0 
         0          21          3          24 
                                             
    stage1           0          1       Total
                    stage3
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E-cadherin expression: Stage 2 vs Stage 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                100.00      100.00 
                  12.0        12.0 
     Total          12          12 
                                  
                 25.00       25.00 
                   3.0         3.0 
         1           3           3 
                                  
                 75.00       75.00 
                   9.0         9.0 
         0           9           9 
                                  
    Stage2           0       Total
               Stage3
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